<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1425" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1425/" /><meta name="ncbi_pagename" content="C3 Glomerulopathy - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>C3 Glomerulopathy - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="C3 Glomerulopathy" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2018/04/05" /><meta name="citation_author" content="Bertha Martín" /><meta name="citation_author" content="Richard JH Smith" /><meta name="citation_pmid" content="20301598" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1425/" /><meta name="citation_keywords" content="C3G" /><meta name="citation_keywords" content="Glomerulonephritis with Dominant C3" /><meta name="citation_keywords" content="Glomerulonephritis with Dominant C3" /><meta name="citation_keywords" content="C3G" /><meta name="citation_keywords" content="Complement C3" /><meta name="citation_keywords" content="Complement factor B" /><meta name="citation_keywords" content="Complement factor H" /><meta name="citation_keywords" content="Complement factor H-related protein 1" /><meta name="citation_keywords" content="Complement factor H-related protein 5" /><meta name="citation_keywords" content="Complement factor I" /><meta name="citation_keywords" content="Diacylglycerol kinase epsilon" /><meta name="citation_keywords" content="Membrane cofactor protein" /><meta name="citation_keywords" content="C3" /><meta name="citation_keywords" content="CD46" /><meta name="citation_keywords" content="CFB" /><meta name="citation_keywords" content="CFH" /><meta name="citation_keywords" content="CFHR1" /><meta name="citation_keywords" content="CFHR5" /><meta name="citation_keywords" content="CFI" /><meta name="citation_keywords" content="DGKE" /><meta name="citation_keywords" content="C3 Glomerulopathy" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="C3 Glomerulopathy" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Bertha Martín" /><meta name="DC.Contributor" content="Richard JH Smith" /><meta name="DC.Date" content="2018/04/05" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1425/" /><meta name="description" content="C3 glomerulopathy (C3G) is a complex ultra-rare complement-mediated renal disease caused by uncontrolled activation of the complement alternative pathway (AP) in the fluid phase (as opposed to cell surface) that is rarely inherited in a simple mendelian fashion. C3G affects individuals of all ages, with a median age at diagnosis of 23 years. Individuals with C3G typically present with hematuria, proteinuria, hematuria and proteinuria, acute nephritic syndrome or nephrotic syndrome, and low levels of the complement component C3. Spontaneous remission of C3G is uncommon, and about half of affected individuals develop end-stage renal disease (ESRD) within ten years of diagnosis, occasionally developing the late comorbidity of impaired visual acuity." /><meta name="og:title" content="C3 Glomerulopathy" /><meta name="og:type" content="book" /><meta name="og:description" content="C3 glomerulopathy (C3G) is a complex ultra-rare complement-mediated renal disease caused by uncontrolled activation of the complement alternative pathway (AP) in the fluid phase (as opposed to cell surface) that is rarely inherited in a simple mendelian fashion. C3G affects individuals of all ages, with a median age at diagnosis of 23 years. Individuals with C3G typically present with hematuria, proteinuria, hematuria and proteinuria, acute nephritic syndrome or nephrotic syndrome, and low levels of the complement component C3. Spontaneous remission of C3G is uncommon, and about half of affected individuals develop end-stage renal disease (ESRD) within ten years of diagnosis, occasionally developing the late comorbidity of impaired visual acuity." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1425/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/mpgn/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1425/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8D1A2BE03FC6010000000006EE026D.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1425_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1425_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/burn-mckeown/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/als-ftd/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1425_"><span class="title" itemprop="name">C3 Glomerulopathy</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonyms: C3G, Glomerulonephritis with Dominant C3</div><p class="contrib-group"><span itemprop="author">Bertha Mart&#x000ed;n</span>, PhD candidate and <span itemprop="author">Richard JH Smith</span>, MD.</p><a data-jig="ncbitoggler" href="#__NBK1425_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1425_ai__"><div class="contrib half_rhythm"><span itemprop="author">Bertha Mart&#x000ed;n</span>, PhD candidate<div class="affiliation small">Molecular Otolaryngology and Renal Research Laboratories<br />Anatomy and Cell Biology Department<br />University of Iowa<br />Iowa City, Iowa</div></div><div class="contrib half_rhythm"><span itemprop="author">Richard JH Smith</span>, MD<div class="affiliation small">Professor of Internal Medicine, Division of Nephrology<br />Sterba Hearing Research Professor of Otolaryngology<br />Director, Molecular Otolaryngology and Renal Research Laboratories<br />University of Iowa<br />Iowa City, Iowa</div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">July 20, 2007</span>; Last Update: <span itemprop="dateModified">April 5, 2018</span>.</p><p><em>Estimated reading time: 39 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="mpgn.Summary" itemprop="description"><h2 id="_mpgn_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>C3 glomerulopathy (C3G) is a complex ultra-rare complement-mediated renal disease caused by uncontrolled activation of the complement alternative pathway (AP) in the fluid phase (as opposed to cell surface) that is rarely inherited in a simple mendelian fashion. C3G affects individuals of all ages, with a median age at diagnosis of 23 years. Individuals with C3G typically present with hematuria, proteinuria, hematuria and proteinuria, acute nephritic syndrome or nephrotic syndrome, and low levels of the complement component C3. Spontaneous remission of C3G is uncommon, and about half of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals develop end-stage renal disease (ESRD) within ten years of diagnosis, occasionally developing the late comorbidity of impaired visual acuity.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The definitive diagnosis of C3G requires a renal biopsy with specialized immunofluorescence and electron microscopy studies both for diagnosis and to distinguish between the two major subtypes of C3G: C3 glomerulonephritis (C3GN) and dense deposit disease (DDD). Some individuals will have <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> or <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> pathogenic variants identified by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> in one or more of the genes that have been implicated in the pathogenesis of C3G (i.e., <i>C3</i>, <i>CD46</i>, <i>CFB</i>, <i>CFH</i>, <i>CFHR1</i>, <i>CFHR5</i>, <i>CFI</i>, and <i>DGKE</i>).</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Nonspecific therapies used to treat numerous chronic glomerular diseases, including angiotensin-converting enzyme inhibitors, angiotensin II type-1 receptor blockers, and lipid-lowering agents (in particular hydroxymethylglutaryl coenzyme A reductase inhibitors). Complement inhibition with a terminal pathway blocker may alter disease course in some individuals. When ESRD develops, treatment options are limited to dialysis or transplantation. C3G recurs in nearly all grafts and is the predominant cause of graft failure in 50%-90% of transplant recipients.</p><p><i>Prevention of primary manifestations:</i> Plasma replacement therapy in individuals with pathogenic variants in <i>CFH</i> may be effective in controlling complement activation and slowing progression of ESRD.</p><p><i>Surveillance:</i> Close monitoring of renal function by a nephrologist with familiarity with the C3G disease spectrum, complete biannual assessment of the complement pathway, periodic eye examinations to evaluate the fundus.</p><p><i>Evaluation of relatives at risk:</i> If the family history is positive for renal disease, evaluation of apparently asymptomatic at-risk relatives can include <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (if the pathogenic variants in the family are known), urinalysis, and comprehensive analysis of the complement system.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>C3G is a complex genetic disorder that is rarely inherited in a simple mendelian fashion. Multiple <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> persons within a single nuclear family are reported only occasionally, with both dominant and recessive inheritance being described.</p></div></div><div id="mpgn.Diagnosis"><h2 id="_mpgn_Diagnosis_">Diagnosis</h2><p>C3 glomerulopathy (C3G) is a complex ultra-rare complement-mediated renal disease caused by uncontrolled activation of the complement alternative pathway (AP) in the fluid phase (as opposed to cell surface); it is rarely inherited in a simple mendelian fashion.</p><div id="mpgn.Suggestive_Findings"><h3>Suggestive Findings</h3><p>C3G <b>should be suspected</b> in individuals of all ages who present with one of the following:</p><ul><li class="half_rhythm"><div>Hematuria</div></li><li class="half_rhythm"><div>Proteinuria</div></li><li class="half_rhythm"><div>Hematuria and proteinuria</div></li><li class="half_rhythm"><div>Acute nephritic syndrome</div></li><li class="half_rhythm"><div>Nephrotic syndrome</div></li><li class="half_rhythm"><div>Persistent hypocomplementemia (low serum levels of complement component C3)</div></li></ul></div><div id="mpgn.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>The diagnosis of C3G <b>is established</b> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with typical findings on <b>renal biopsy</b>. Some individuals will have <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> or <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> pathogenic variants identified by <b><a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a></b> in one or more of the genes listed in <a class="figpopup" href="/books/NBK1425/table/mpgn.T.molecular_genetic_testing_used_in/?report=objectonly" target="object" rid-figpopup="figmpgnTmoleculargenetictestingusedin" rid-ob="figobmpgnTmoleculargenetictestingusedin">Table 1</a>.</p><p>Note: Identification of a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> may help to direct treatment of the individual.</p><p><b>Renal biopsy.</b> The definitive diagnosis of C3G requires a renal biopsy with specialized studies (see <a class="figpopup" href="/books/NBK1425/figure/mpgn.F1/?report=objectonly" target="object" rid-figpopup="figmpgnF1" rid-ob="figobmpgnF1">Figure 1</a>) both for diagnosis and to distinguish between C3 glomerulonephritis (C3GN) and dense deposit disease (DDD).</p><div class="iconblock whole_rhythm clearfix ten_col fig" id="figmpgnF1" co-legend-rid="figlgndmpgnF1"><a href="/books/NBK1425/figure/mpgn.F1/?report=objectonly" target="object" title="Figure 1. " class="img_link icnblk_img figpopup" rid-figpopup="figmpgnF1" rid-ob="figobmpgnF1"><img class="small-thumb" src="/books/NBK1425/bin/mpgn-Image001.gif" src-large="/books/NBK1425/bin/mpgn-Image001.jpg" alt="Figure 1. " /></a><div class="icnblk_cntnt" id="figlgndmpgnF1"><h4 id="mpgn.F1"><a href="/books/NBK1425/figure/mpgn.F1/?report=objectonly" target="object" rid-ob="figobmpgnF1">Figure 1. </a></h4><p class="float-caption no_bottom_margin">Disease-specific characteristic IF, EM, and LM biopsy images in C3 glomerulopathy (C3G) A. Immunofluoresence (IF) shows bright staining for C3, which must be at least two orders of magnitude greater than any other immune reactant. Note the diffuse glomerular <a href="/books/NBK1425/figure/mpgn.F1/?report=objectonly" target="object" rid-ob="figobmpgnF1">(more...)</a></p></div></div><ul><li class="half_rhythm"><div class="half_rhythm">Immunofluorescence (IF). The diagnosis of C3G can only be made with IF studies of a renal biopsy.</div><ul><li class="half_rhythm"><div>The predominant staining of C3 is key in delivering a C3G diagnosis.</div></li><li class="half_rhythm"><div>IF should be predominantly positive for C3 with C3 intensity at least two orders of magnitude greater than any other immune reactant (i.e., IgA, IgG, IgM, and C1q) (<a class="figpopup" href="/books/NBK1425/figure/mpgn.F1/?report=objectonly" target="object" rid-figpopup="figmpgnF1" rid-ob="figobmpgnF1">Figure 1A</a>).</div></li></ul></li><li class="half_rhythm"><div class="half_rhythm">Electron microscopy (EM) is used to distinguish between C3GN and DDD, a clinically relevant distinction (<a class="figpopup" href="/books/NBK1425/figure/mpgn.F1/?report=objectonly" target="object" rid-figpopup="figmpgnF1" rid-ob="figobmpgnF1">Figure 1</a>). EM should demonstrate dense transformation of the glomerulus.</div><ul><li class="half_rhythm"><div>In C3GN there are light, hump-like and clustered deposits, which are found in the mesangium or in the subendothelial and/or subepithelial spaces.</div></li><li class="half_rhythm"><div>In DDD, the deposits are darker, denser, segmental, discontinuous, ribbon-like, or diffuse and are most frequently located in the lamina densa of the glomerular basement membrane (GBM) (<a class="figpopup" href="/books/NBK1425/figure/mpgn.F1/?report=objectonly" target="object" rid-figpopup="figmpgnF1" rid-ob="figobmpgnF1">Figure 1B-C</a>).</div></li></ul></li><li class="half_rhythm"><div class="half_rhythm">Light microscopy (LM) is necessary to quantitate changes associated with chronic kidney disease and risk for progression of ESRD.</div><div class="half_rhythm">LM most commonly demonstrates mild mesangial cell hypercellularity (45% of cases), although membranoproliferative (25%), crescentic (18%), and acute proliferative and exudative (12%) patterns are also seen (<a class="figpopup" href="/books/NBK1425/figure/mpgn.F1/?report=objectonly" target="object" rid-figpopup="figmpgnF1" rid-ob="figobmpgnF1">Figure 1D</a>).</div></li></ul><p>Note: Timing of the biopsy is important. If the presentation suggests post-infectious glomerulonephritis (PIGN; see <a class="figpopup" href="/books/NBK1425/figure/mpgn.F2/?report=objectonly" target="object" rid-figpopup="figmpgnF2" rid-ob="figobmpgnF2">Figure 2</a>), waiting for three months is typically recommended. During that interval, the hypocomplementemia, hematuria, and proteinuria that are characteristic of both PIGN and C3G should resolve in cases of PIGN [<a class="bk_pop" href="#mpgn.REF.walker.2007.605">Walker et al 2007</a>, <a class="bk_pop" href="#mpgn.REF.nester.2016.241">Nester &#x00026; Smith 2016</a>, <a class="bk_pop" href="#mpgn.REF.goodship.2017.539">Goodship et al 2017</a>].</p><div class="iconblock whole_rhythm clearfix ten_col fig" id="figmpgnF2" co-legend-rid="figlgndmpgnF2"><a href="/books/NBK1425/figure/mpgn.F2/?report=objectonly" target="object" title="Figure 2. " class="img_link icnblk_img figpopup" rid-figpopup="figmpgnF2" rid-ob="figobmpgnF2"><img class="small-thumb" src="/books/NBK1425/bin/mpgn-Image002.gif" src-large="/books/NBK1425/bin/mpgn-Image002.jpg" alt="Figure 2. " /></a><div class="icnblk_cntnt" id="figlgndmpgnF2"><h4 id="mpgn.F2"><a href="/books/NBK1425/figure/mpgn.F2/?report=objectonly" target="object" rid-ob="figobmpgnF2">Figure 2. </a></h4><p class="float-caption no_bottom_margin">Schematic representation of disease types Post-infectious glomerulonephritis (PIGN), C3 glomerulopathy (C3G), and other disease types fall under the classification "glomerular diseases with dominant C3" immunofluorescence (IF) staining, with the term <a href="/books/NBK1425/figure/mpgn.F2/?report=objectonly" target="object" rid-ob="figobmpgnF2">(more...)</a></p></div></div><p><b>Molecular genetic testing</b> approaches can include a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>, <b>more comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b>, and <b>serial single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b>:</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>C3</i>, <i>CD46</i>, <i>CFB</i>, <i>CFH</i>, <i>CFHR1</i>, <i>CFHR5</i>, <i>CFI</i>, <i>DGKE</i>, and other genes of interest (see <a href="#mpgn.Differential_Diagnosis">Differential Diagnosis</a>) may be considered. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>; thus, clinicians need to determine which multigene panel is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</div><div class="half_rhythm">For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</div><div class="half_rhythm"><b>Note:</b> Analysis of <i>CFH</i>-related genes is complicated by the high degree of sequence identity between <i>CFH</i> and the downstream <i>CFH</i>-related genes (<i>CFHR1-CFHR5</i>). This similarity results in susceptibility to <a class="def" href="/books/n/gene/glossary/def-item/nonallelic-homologous-recombination/">nonallelic homologous recombination</a> (NAHR) events, large-scale deletions or duplications (copy number variants), and generation of hybrid <i>CFH</i> genes. Molecular assays must be specifically designed to detect the spectrum of changes that can occur in this region.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>More comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> (when available) including <a class="def" href="/books/n/gene/glossary/def-item/exome-sequencing/">exome sequencing</a> and <a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a> may be considered. Such testing may provide or suggest a diagnosis not previously considered (e.g., mutation of a different <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> or genes that results in a similar clinical presentation).</div><div class="half_rhythm">For an introduction to comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing click <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing">here</a>. More detailed information for clinicians ordering genomic testing can be found <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing_1">here</a>.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Serial single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing.</b> Sequence analysis can be performed on a gene-by-gene basis, although this approach is generally not recommended because there are no phenotypic clues to inform the order of genes to be tested and because rare/novel variants can be present in multiple genes [<a class="bk_pop" href="#mpgn.REF.bu.2016.1245">Bu et al 2016</a>]. If single-gene testing is performed, gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a>/<a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a> testing over the <i>CFHR1-CFHR5</i> region should also be completed in all cases.</div></li></ul><div id="mpgn.T.molecular_genetic_testing_used_in" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in C3G</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1425/table/mpgn.T.molecular_genetic_testing_used_in/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__mpgn.T.molecular_genetic_testing_used_in_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_mpgn.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_mpgn.T.molecular_genetic_testing_used_in_1_1_1_1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1,&#x000a0;2</sup></th><th id="hd_h_mpgn.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_mpgn.T.molecular_genetic_testing_used_in_1_1_1_2" style="text-align:left;vertical-align:middle;">Proportion of C3G Attributed to Pathogenic Variants in Gene</th><th id="hd_h_mpgn.T.molecular_genetic_testing_used_in_1_1_1_3" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Proportion of Pathogenic Variants&#x000a0;<sup>3</sup> Detectable by Method</th></tr><tr><th headers="hd_h_mpgn.T.molecular_genetic_testing_used_in_1_1_1_3" id="hd_h_mpgn.T.molecular_genetic_testing_used_in_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>4</sup></th><th headers="hd_h_mpgn.T.molecular_genetic_testing_used_in_1_1_1_3" id="hd_h_mpgn.T.molecular_genetic_testing_used_in_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>5</sup></th></tr></thead><tbody><tr><td headers="hd_h_mpgn.T.molecular_genetic_testing_used_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>C3</i></td><td headers="hd_h_mpgn.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~11%&#x000a0;<sup>6</sup></td><td headers="hd_h_mpgn.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_mpgn.T.molecular_genetic_testing_used_in_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~100%</td><td headers="hd_h_mpgn.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_mpgn.T.molecular_genetic_testing_used_in_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown</td></tr><tr><td headers="hd_h_mpgn.T.molecular_genetic_testing_used_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>CD46</i></td><td headers="hd_h_mpgn.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0%~2%&#x000a0;<sup>7</sup></td><td headers="hd_h_mpgn.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_mpgn.T.molecular_genetic_testing_used_in_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">100%</td><td headers="hd_h_mpgn.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_mpgn.T.molecular_genetic_testing_used_in_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown</td></tr><tr><td headers="hd_h_mpgn.T.molecular_genetic_testing_used_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>CFB</i></td><td headers="hd_h_mpgn.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;1%&#x000a0;<sup>8</sup></td><td headers="hd_h_mpgn.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_mpgn.T.molecular_genetic_testing_used_in_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">100%</td><td headers="hd_h_mpgn.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_mpgn.T.molecular_genetic_testing_used_in_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown</td></tr><tr><td headers="hd_h_mpgn.T.molecular_genetic_testing_used_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>CFH</i></td><td headers="hd_h_mpgn.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~12%&#x000a0;<sup>9</sup></td><td headers="hd_h_mpgn.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_mpgn.T.molecular_genetic_testing_used_in_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~98%</td><td headers="hd_h_mpgn.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_mpgn.T.molecular_genetic_testing_used_in_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~2%</td></tr><tr><td headers="hd_h_mpgn.T.molecular_genetic_testing_used_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>CFHR1</i><br /><a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a>&#x000a0;<sup>10</sup></td><td headers="hd_h_mpgn.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2 individuals</td><td headers="hd_h_mpgn.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_mpgn.T.molecular_genetic_testing_used_in_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">NA</td><td headers="hd_h_mpgn.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_mpgn.T.molecular_genetic_testing_used_in_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">100%&#x000a0;<sup>11</sup></td></tr><tr><td headers="hd_h_mpgn.T.molecular_genetic_testing_used_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>CFHR1/CFHR5</i> hybrid <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>&#x000a0;<sup>10</sup></td><td headers="hd_h_mpgn.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">3 individuals</td><td headers="hd_h_mpgn.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_mpgn.T.molecular_genetic_testing_used_in_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">NA</td><td headers="hd_h_mpgn.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_mpgn.T.molecular_genetic_testing_used_in_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">100%&#x000a0;<sup>12</sup></td></tr><tr><td headers="hd_h_mpgn.T.molecular_genetic_testing_used_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>CFHR3/CFHR1</i> hybrid <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>&#x000a0;<sup>10</sup></td><td headers="hd_h_mpgn.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">5 individuals</td><td headers="hd_h_mpgn.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_mpgn.T.molecular_genetic_testing_used_in_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">NA</td><td headers="hd_h_mpgn.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_mpgn.T.molecular_genetic_testing_used_in_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">100%&#x000a0;<sup>13</sup></td></tr><tr><td headers="hd_h_mpgn.T.molecular_genetic_testing_used_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>CFHR5</i></td><td headers="hd_h_mpgn.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">See footnote 14</td><td headers="hd_h_mpgn.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_mpgn.T.molecular_genetic_testing_used_in_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">See footnote 15</td><td headers="hd_h_mpgn.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_mpgn.T.molecular_genetic_testing_used_in_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown (general population); 100% (Cyprus)&#x000a0;<sup>14</sup></td></tr><tr><td headers="hd_h_mpgn.T.molecular_genetic_testing_used_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>CFHR5/CFHR2</i> hybrid <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>&#x000a0;<sup>10</sup></td><td headers="hd_h_mpgn.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2 individuals</td><td headers="hd_h_mpgn.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_mpgn.T.molecular_genetic_testing_used_in_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">NA</td><td headers="hd_h_mpgn.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_mpgn.T.molecular_genetic_testing_used_in_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">100%&#x000a0;<sup>16</sup></td></tr><tr><td headers="hd_h_mpgn.T.molecular_genetic_testing_used_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>CFI</i></td><td headers="hd_h_mpgn.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~5%&#x000a0;<sup>17</sup></td><td headers="hd_h_mpgn.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_mpgn.T.molecular_genetic_testing_used_in_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">100%</td><td headers="hd_h_mpgn.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_mpgn.T.molecular_genetic_testing_used_in_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown</td></tr><tr><td headers="hd_h_mpgn.T.molecular_genetic_testing_used_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>DGK&#x00395;</i></td><td headers="hd_h_mpgn.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">13 individuals&#x000a0;<sup>18</sup></td><td headers="hd_h_mpgn.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_mpgn.T.molecular_genetic_testing_used_in_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~100%</td><td headers="hd_h_mpgn.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_mpgn.T.molecular_genetic_testing_used_in_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="mpgn.TF.1.1"><p class="no_margin">Genes are listed in alphabetic order.</p></div></dd><dt>2. </dt><dd><div id="mpgn.TF.1.2"><p class="no_margin">See <a href="/books/NBK1425/#mpgn.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>3. </dt><dd><div id="mpgn.TF.1.3"><p class="no_margin">See <a href="#mpgn.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>4. </dt><dd><div id="mpgn.TF.1.4"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>5. </dt><dd><div id="mpgn.TF.1.5"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods used may include: <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd><dt>6. </dt><dd><div id="mpgn.TF.1.6"><p class="no_margin"><a class="bk_pop" href="#mpgn.REF.mart_nezbarricarte.2010.3702">Mart&#x000ed;nez-Barricarte et al [2010]</a>, <a class="bk_pop" href="#mpgn.REF.abreraabeleda.2011.1551">Abrera-Abeleda et al [2011]</a>, <a class="bk_pop" href="#mpgn.REF.imamura.2015.862">Imamura et al [2015]</a>, <a class="bk_pop" href="#mpgn.REF.bu.2016.1245">Bu et al [2016]</a>, <a class="bk_pop" href="#mpgn.REF.iatropoulos.2016.131">Iatropoulos et al [2016]</a></p></div></dd><dt>7. </dt><dd><div id="mpgn.TF.1.7"><p class="no_margin"><a class="bk_pop" href="#mpgn.REF.servais.2012.454">Servais et al [2012]</a>, <a class="bk_pop" href="#mpgn.REF.nester.2013a.395">Nester &#x00026; Smith [2013a]</a></p></div></dd><dt>8. </dt><dd><div id="mpgn.TF.1.8"><p class="no_margin"><a class="bk_pop" href="#mpgn.REF.imamura.2015.862">Imamura et al [2015]</a></p></div></dd><dt>9. </dt><dd><div id="mpgn.TF.1.9"><p class="no_margin"><a class="bk_pop" href="#mpgn.REF.ault.1997.25168">Ault et al [1997]</a>, <a class="bk_pop" href="#mpgn.REF.dragondurey.2004.787">Dragon-Durey et al [2004]</a>, <a class="bk_pop" href="#mpgn.REF.licht.2006.42">Licht et al [2006]</a>, <a class="bk_pop" href="#mpgn.REF.servais.2012.454">Servais et al [2012]</a>, <a class="bk_pop" href="#mpgn.REF.sethi.2012b.434">Sethi et al [2012b]</a>, <a class="bk_pop" href="#mpgn.REF.zhang.2012.265">Zhang et al [2012]</a>, <a class="bk_pop" href="#mpgn.REF.johnson.2014.1883">Johnson et al [2014]</a>, <a class="bk_pop" href="#mpgn.REF.bu.2016.1245">Bu et al [2016]</a>, <a class="bk_pop" href="#mpgn.REF.iatropoulos.2016.131">Iatropoulos et al [2016]</a></p></div></dd><dt>10. </dt><dd><div id="mpgn.TF.1.10"><p class="no_margin"><i>CFHR</i> hybrid alleles are the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> fusion products of <a class="def" href="/books/n/gene/glossary/def-item/nonallelic-homologous-recombination/">nonallelic homologous recombination</a> between the highly homologous <i>CFHR</i> genes [<a class="bk_pop" href="#mpgn.REF.gale.2010.794">Gale et al 2010</a>, <a class="bk_pop" href="#mpgn.REF.malik.2012.1155">Malik et al 2012</a>, <a class="bk_pop" href="#mpgn.REF.tortajada.2013.2434">Tortajada et al 2013</a>, <a class="bk_pop" href="#mpgn.REF.chen.2014.145">Chen et al 2014</a>, <a class="bk_pop" href="#mpgn.REF.medjeralthomas.2014.933">Medjeral-Thomas et al 2014</a>, <a class="bk_pop" href="#mpgn.REF.xiao.2016.89">Xiao et al 2016</a>, <a class="bk_pop" href="#mpgn.REF.togarsimalemath.2017.876">Togarsimalemath et al 2017</a>] (for details of <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> arrangements see <a class="figpopup" href="/books/NBK1425/figure/mpgn.F3/?report=objectonly" target="object" rid-figpopup="figmpgnF3" rid-ob="figobmpgnF3">Figure 3</a>).</p></div></dd><dt>11. </dt><dd><div id="mpgn.TF.1.11"><p class="no_margin"><a class="bk_pop" href="#mpgn.REF.tortajada.2013.2434">Tortajada et al [2013]</a></p></div></dd><dt>12. </dt><dd><div id="mpgn.TF.1.12"><p class="no_margin"><a class="bk_pop" href="#mpgn.REF.togarsimalemath.2017.876">Togarsimalemath et al [2017]</a></p></div></dd><dt>13. </dt><dd><div id="mpgn.TF.1.13"><p class="no_margin"><a class="bk_pop" href="#mpgn.REF.malik.2012.1155">Malik et al [2012]</a></p></div></dd><dt>14. </dt><dd><div id="mpgn.TF.1.14"><p class="no_margin">Four individuals of non-Cypriot origin; however, hundreds of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals with a <a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a> of exons 2 and 3, presumably due to a <a class="def" href="/books/n/gene/glossary/def-item/founder-effect/">founder effect</a>, have been identified in Cyprus [<a class="bk_pop" href="#mpgn.REF.gale.2010.794">Gale et al 2010</a>, <a class="bk_pop" href="#mpgn.REF.athanasiou.2011.1436">Athanasiou et al 2011</a>, <a class="bk_pop" href="#mpgn.REF.deltas.2013.189">Deltas et al 2013</a>].</p></div></dd><dt>15. </dt><dd><div id="mpgn.TF.1.15"><p class="no_margin">Three patients of non-Cypriot origin have been reported with variants detectable by sequencing [<a class="bk_pop" href="#mpgn.REF.sethi.2012a.465">Sethi et al 2012a</a>, <a class="bk_pop" href="#mpgn.REF.vernon.2012.121">Vernon et al 2012</a>, <a class="bk_pop" href="#mpgn.REF.besbas.2014.457">Besbas et al 2014</a>].</p></div></dd><dt>16. </dt><dd><div id="mpgn.TF.1.16"><p class="no_margin"><a class="bk_pop" href="#mpgn.REF.chen.2014.145">Chen et al [2014]</a>, <a class="bk_pop" href="#mpgn.REF.medjeralthomas.2014.933">Medjeral-Thomas et al [2014]</a>, <a class="bk_pop" href="#mpgn.REF.xiao.2016.89">Xiao et al [2016]</a></p></div></dd><dt>17. </dt><dd><div id="mpgn.TF.1.17"><p class="no_margin"><a class="bk_pop" href="#mpgn.REF.servais.2012.454">Servais et al [2012]</a>, <a class="bk_pop" href="#mpgn.REF.nester.2016.241">Nester &#x00026; Smith [2016]</a></p></div></dd><dt>18. </dt><dd><div id="mpgn.TF.1.18"><p class="no_margin"><a class="bk_pop" href="#mpgn.REF.ozaltin.2013.377">Ozaltin et al [2013]</a>, <a class="bk_pop" href="#mpgn.REF.westland.2014.1408">Westland et al [2014]</a>, <a class="bk_pop" href="#mpgn.REF.azukaitis.2017.3066">Azukaitis et al [2017]</a></p></div></dd></dl></div></div></div><p>See <a class="figpopup" href="/books/NBK1425/figure/mpgn.F3/?report=objectonly" target="object" rid-figpopup="figmpgnF3" rid-ob="figobmpgnF3">Figure 3</a>.</p><div class="iconblock whole_rhythm clearfix ten_col fig" id="figmpgnF3" co-legend-rid="figlgndmpgnF3"><a href="/books/NBK1425/figure/mpgn.F3/?report=objectonly" target="object" title="Figure 3. " class="img_link icnblk_img figpopup" rid-figpopup="figmpgnF3" rid-ob="figobmpgnF3"><img class="small-thumb" src="/books/NBK1425/bin/mpgn-Image003.gif" src-large="/books/NBK1425/bin/mpgn-Image003.jpg" alt="Figure 3. " /></a><div class="icnblk_cntnt" id="figlgndmpgnF3"><h4 id="mpgn.F3"><a href="/books/NBK1425/figure/mpgn.F3/?report=objectonly" target="object" rid-ob="figobmpgnF3">Figure 3. </a></h4><p class="float-caption no_bottom_margin">Complement factor H-related hybrid proteins and C3G Adapted from Togarsimalemath et al [2017] and references therein</p></div></div></div></div><div id="mpgn.Clinical_Characteristics"><h2 id="_mpgn_Clinical_Characteristics_">Clinical Characteristics</h2><div id="mpgn.Clinical_Description"><h3>Clinical Description</h3><p><b>Age of onset.</b> C3 glomerulopathy (C3G) affects individuals of all ages. <a class="bk_pop" href="#mpgn.REF.lu.2012.773">Lu et al [2012]</a> report a 1:1 female:male distribution and a median age at diagnosis of 23 years.</p><p>In comparing the two major subtypes, the median age at time of diagnosis in C3 glomerulonephritis (C3GN) is higher than in dense deposit disease (DDD). In childhood, DDD is more frequently diagnosed than C3GN [<a class="bk_pop" href="#mpgn.REF.nester.2016.241">Nester &#x00026; Smith 2016</a>, <a class="bk_pop" href="#mpgn.REF.riedl.2017.43">Riedl et al 2017</a>].</p><p><b>Renal disease.</b> Individuals with C3G typically present with one of the following findings:</p><ul><li class="half_rhythm"><div>Hematuria</div></li><li class="half_rhythm"><div>Proteinuria</div></li><li class="half_rhythm"><div>Hematuria and proteinuria</div></li><li class="half_rhythm"><div>Acute nephritic syndrome</div></li><li class="half_rhythm"><div>Nephrotic syndrome</div></li></ul><p><b>Hypocomplementemia.</b> Individuals with C3G have low levels of complement component C3. Complement dysregulation can be mediated by autoantibodies (see <a href="#mpgn.Pathophysiology">Pathophysiology</a>).</p><p>Autoantibodies that may be detected in individuals with C3G:</p><ul><li class="half_rhythm"><div>Serum C3 nephritic factor (C3NeFs). C3NeFs are present in up to ~50% of individuals with C3GN and ~80% of individuals with DDD [<a class="bk_pop" href="#mpgn.REF.salvadori.2016.632">Salvadori &#x00026; Bertoni 2016</a>].</div></li><li class="half_rhythm"><div>Factor H autoantibodies (FHAAs). <a class="bk_pop" href="#mpgn.REF.blanc.2015.5129">Blanc et al [2015]</a> reported the prevalence of FHAAs in C3G individuals to be 11%.</div></li><li class="half_rhythm"><div>Factor B autoantibodies (FBAAs). FBAAs have been linked to C3G; their role in disease remains unclear [<a class="bk_pop" href="#mpgn.REF.pickering.2013.1079">Pickering et al 2013</a>].</div></li></ul><p><b>Course and progression</b></p><ul><li class="half_rhythm"><div>Spontaneous remission of C3G is uncommon [<a class="bk_pop" href="#mpgn.REF.habib.1975.204">Habib et al 1975</a>, <a class="bk_pop" href="#mpgn.REF.cameron.1983.175">Cameron et al 1983</a>, <a class="bk_pop" href="#mpgn.REF.marks.2000.322">Marks &#x00026; Rees 2000</a>, <a class="bk_pop" href="#mpgn.REF.thomas.2014.339">Thomas et al 2014</a>]. While the disease can remain stable for years despite persistent proteinuria, in some individuals rapid fluctuations in proteinuria occur, with episodes of acute renal deterioration in the absence of obvious triggering events. Efforts to move individuals to remission have not been successful [<a class="bk_pop" href="#mpgn.REF.daina.2012.1161">Daina et al 2012</a>, <a class="bk_pop" href="#mpgn.REF.mccaughan.2012.1046">McCaughan et al 2012</a>]. Current data suggest that C3G remains a chronic disease subject to acute exacerbations, with constant activation of the complement alternative pathway (AP) [<a class="bk_pop" href="#mpgn.REF.goodship.2017.539">Goodship et al 2017</a>].</div></li><li class="half_rhythm"><div>About half of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals develop end-stage renal disease (ESRD) within ten years of diagnosis [<a class="bk_pop" href="#mpgn.REF.lu.2007.295">Lu et al 2007</a>, <a class="bk_pop" href="#mpgn.REF.servais.2012.454">Servais et al 2012</a>, <a class="bk_pop" href="#mpgn.REF.nester.2016.241">Nester &#x00026; Smith 2016</a>, <a class="bk_pop" href="#mpgn.REF.goodship.2017.539">Goodship et al 2017</a>], occasionally developing the late comorbidity of impaired visual acuity [<a class="bk_pop" href="#mpgn.REF.recalde.2016.1305">Recalde et al 2016</a>].</div><ul><li class="half_rhythm"><div>Progression to ESRD can be rapid [<a class="bk_pop" href="#mpgn.REF.smith.2007.2447">Smith et al 2007</a>, <a class="bk_pop" href="#mpgn.REF.nester.2013b.231">Nester &#x00026; Smith 2013b</a>, <a class="bk_pop" href="#mpgn.REF.servais.2013.185">Servais et al 2013</a>].</div></li><li class="half_rhythm"><div>Age and sex of an individual are not significant predictors of disease course.</div></li><li class="half_rhythm"><div>Native kidney survival is comparable in C3GN and DDD [<a class="bk_pop" href="#mpgn.REF.servais.2013.185">Servais et al 2013</a>, <a class="bk_pop" href="#mpgn.REF.nester.2016.241">Nester &#x00026; Smith 2016</a>].</div></li></ul></li></ul><p><b>Acquired partial lipodystrophy (APL).</b> APL may develop as a direct aftermath of complement activation in 5%-17% of persons with C3G [<a class="bk_pop" href="#mpgn.REF.barbour.2013b.493">Barbour et al 2013b</a>, <a class="bk_pop" href="#mpgn.REF.goodship.2017.539">Goodship et al 2017</a>]. The association between APL and C3G is related to the effects of AP dysregulation on both kidneys and adipose tissue [<a class="bk_pop" href="#mpgn.REF.goodship.2017.539">Goodship et al 2017</a>]. The deposition of activated complement components in adipose tissue destroys adipocytes in areas where factor D (fD, also known as adipsin) is high; loss of subcutaneous fat in the upper half of the body typically precedes the onset of kidney disease by several years.</p><p><b>Eye findings.</b> Individuals with C3G develop drusen as a result of complement activation, often in early adulthood [<a class="bk_pop" href="#mpgn.REF.barbour.2013b.493">Barbour et al 2013b</a>, <a class="bk_pop" href="#mpgn.REF.thomas.2014.339">Thomas et al 2014</a>, <a class="bk_pop" href="#mpgn.REF.goodship.2017.539">Goodship et al 2017</a>]. The whitish-yellow deposits, which lie within Bruch's membrane beneath the retinal pigment epithelium of the retina, are similar in composition and structure to the deposits observed in the kidney [<a class="bk_pop" href="#mpgn.REF.dsouza.2009.824">D'Souza et al 2009</a>, <a class="bk_pop" href="#mpgn.REF.lu.2012.773">Lu et al 2012</a>, <a class="bk_pop" href="#mpgn.REF.barbour.2013b.493">Barbour et al 2013b</a>]. The retinal distribution of drusen is variable [<a class="bk_pop" href="#mpgn.REF.thomas.2014.339">Thomas et al 2014</a>, <a class="bk_pop" href="#mpgn.REF.goodship.2017.539">Goodship et al 2017</a>] and initially has little impact on visual acuity or visual fields. However, vision loss can occur later in life [<a class="bk_pop" href="#mpgn.REF.cebeci.2016.260">Cebeci et al 2016</a>].</p><p>Recent investigations convey the importance of the complications that result from drusen [<a class="bk_pop" href="#mpgn.REF.cebeci.2016.260">Cebeci et al 2016</a>, <a class="bk_pop" href="#mpgn.REF.dalvin.2016.72">Dalvin et al 2016</a>, <a class="bk_pop" href="#mpgn.REF.savige.2016.369">Savige et al 2016</a>]. Tests of retinal function such as dark adaptation, electroretinography, and electrooculography can gradually become abnormal, and vision can deteriorate as subretinal neovascular membranes, macular detachment, and central serous retinopathy develop [<a class="bk_pop" href="#mpgn.REF.cebeci.2016.260">Cebeci et al 2016</a>, <a class="bk_pop" href="#mpgn.REF.dalvin.2016.72">Dalvin et al 2016</a>, <a class="bk_pop" href="#mpgn.REF.savige.2016.369">Savige et al 2016</a>].</p><p>The long-term risk for visual problems in individuals with C3G is approximately 10%. No correlation exists between disease severity in the kidney and in the eye.</p><div id="mpgn.Pathophysiology"><h4>Pathophysiology</h4><p>See <a class="figpopup" href="/books/NBK1425/figure/mpgn.F4/?report=objectonly" target="object" rid-figpopup="figmpgnF4" rid-ob="figobmpgnF4">Figure 4</a>. Fluid-phase dysregulation of the alternate pathway (AP) of the complement cascade is the triggering pathophysiologic event in C3G, and dysregulation of the C3 convertase alone is necessary and sufficient to result in C3G [<a class="bk_pop" href="#mpgn.REF.mart_nezbarricarte.2010.3702">Mart&#x000ed;nez-Barricarte et al 2010</a>, <a class="bk_pop" href="#mpgn.REF.paix_ocavalcante.2012.1084">Paix&#x000e3;o-Cavalcante et al 2012</a>, <a class="bk_pop" href="#mpgn.REF.zhang.2012.265">Zhang et al 2012</a>].</p><div class="iconblock whole_rhythm clearfix ten_col fig" id="figmpgnF4" co-legend-rid="figlgndmpgnF4"><a href="/books/NBK1425/figure/mpgn.F4/?report=objectonly" target="object" title="Figure 4. " class="img_link icnblk_img figpopup" rid-figpopup="figmpgnF4" rid-ob="figobmpgnF4"><img class="small-thumb" src="/books/NBK1425/bin/mpgn-Image004.gif" src-large="/books/NBK1425/bin/mpgn-Image004.jpg" alt="Figure 4. " /></a><div class="icnblk_cntnt" id="figlgndmpgnF4"><h4 id="mpgn.F4"><a href="/books/NBK1425/figure/mpgn.F4/?report=objectonly" target="object" rid-ob="figobmpgnF4">Figure 4. </a></h4><p class="float-caption no_bottom_margin">Complement alternative pathway (AP) <i>Left.</i> Three phases of complement activity are illustrated:</p></div></div><p>During disease progression, activation of downstream complement proteins in the solid phase, in particular cleavage of C5 to C5a and C5b, can contribute to tissue injury in the micro-environment of the renal glomerulus [<a class="bk_pop" href="#mpgn.REF.appel.2005.1392">Appel et al 2005</a>, <a class="bk_pop" href="#mpgn.REF.smith.2007.2447">Smith et al 2007</a>]. Current consensus considers that in C3G, uncontrolled regulation of the AP may be due to both genetic and/or acquired drivers of disease [<a class="bk_pop" href="#mpgn.REF.servais.2012.454">Servais et al 2012</a>, <a class="bk_pop" href="#mpgn.REF.nester.2016.241">Nester &#x00026; Smith 2016</a>, <a class="bk_pop" href="#mpgn.REF.goodship.2017.539">Goodship et al 2017</a>].</p><p>Acquired drivers of disease include autoantibodies such as C3 nephritic factors (C3NeFs), C4 nephritic factors (C4NeFs), C5 nephritic factors (C5NeFs), factor H autoantibodies (FHAA), and factor B autoantibodies (FBAA).</p><p>C3NeFs and C5NeFs are most commonly detected and are autoantibodies that recognize neoantigenic epitopes on C3bBb, the C3 convertase of the AP, and on C3bBbC3b, the C5 convertase of the terminal pathway, respectively (see <a class="figpopup" href="/books/NBK1425/figure/mpgn.F4/?report=objectonly" target="object" rid-figpopup="figmpgnF4" rid-ob="figobmpgnF4">Figure 4</a>) [<a class="bk_pop" href="#mpgn.REF.paix_ocavalcante.2012.1084">Paix&#x000e3;o-Cavalcante et al 2012</a>, <a class="bk_pop" href="#mpgn.REF.zhang.2012.265">Zhang et al 2012</a>, <a class="bk_pop" href="#mpgn.REF.nester.2013a.395">Nester &#x00026; Smith 2013a</a>, <a class="bk_pop" href="#mpgn.REF.nicolas.2014.85">Nicolas et al 2014</a>]. C3 convertases cleave C3 into C3b and C3a, while C5 convertases cleave C5 into C5a and C5b. In the presence of C3NeFs and C5NeFs, the half-lives of C3 convertase and C5 convertase are increased. Persistent cleavage of C3 drives down serum concentrations of C3 and increases serum concentrations of its cleavage products, C3c and C3d, while persistent cleavage of C5 increases serum concentrations of soluble C5b-9. C4NeFs are found in fewer than 5% of individuals with C3GN and stabilize the C3 convertase of the classic and lectin pathways (C4b2a) [<a class="bk_pop" href="#mpgn.REF.zhang.2017.834">Zhang et al 2017</a>].</p><p>Nephritic factors may persist in serum throughout the disease course [<a class="bk_pop" href="#mpgn.REF.schwertz.2001.166">Schwertz et al 2001</a>, <a class="bk_pop" href="#mpgn.REF.paix_ocavalcante.2012.1084">Paix&#x000e3;o-Cavalcante et al 2012</a>, <a class="bk_pop" href="#mpgn.REF.zhang.2012.265">Zhang et al 2012</a>]. Serum concentrations of C3NeFs can vary over time [<a class="bk_pop" href="#mpgn.REF.appel.2005.1392">Appel et al 2005</a>, <a class="bk_pop" href="#mpgn.REF.paix_ocavalcante.2012.1084">Paix&#x000e3;o-Cavalcante et al 2012</a>, <a class="bk_pop" href="#mpgn.REF.zhang.2012.265">Zhang et al 2012</a>, <a class="bk_pop" href="#mpgn.REF.servais.2013.185">Servais et al 2013</a>, <a class="bk_pop" href="#mpgn.REF.rabasco.2015.1153">Rabasco et al 2015</a>]. Their presence is nearly always associated with evidence of complement activation such as decrease in serum concentration of C3 and increase in serum concentration of C3 cleavage products (e.g., C3c and C3d), but the relationship between nephritic factors, C3, and prognosis is not clear [<a class="bk_pop" href="#mpgn.REF.paix_ocavalcante.2012.1084">Paix&#x000e3;o-Cavalcante et al 2012</a>, <a class="bk_pop" href="#mpgn.REF.zhang.2012.265">Zhang et al 2012</a>, <a class="bk_pop" href="#mpgn.REF.rabasco.2015.1153">Rabasco et al 2015</a>]. The observed differences may be reconciled by several observations relevant to C3NeFs, which have been most thoroughly studied. First, not all C3NeFs recognize the same epitope on C3bBb; second, the methods for their detection vary; third, many studies do not report titers; and fourth, there is good evidence that the triggering epitopes can change over time [<a class="bk_pop" href="#mpgn.REF.ohi.1992.479">Ohi et al 1992</a>, <a class="bk_pop" href="#mpgn.REF.spitzer.1996.211">Spitzer &#x00026; Stitzel 1996</a>, <a class="bk_pop" href="#mpgn.REF.paix_ocavalcante.2012.1084">Paix&#x000e3;o-Cavalcante et al 2012</a>, <a class="bk_pop" href="#mpgn.REF.zhang.2012.265">Zhang et al 2012</a>].</p><p>The consequence of AP dysregulation in C3G is kidney damage. As the degree of chronic damage increases, renal outcome ultimately becomes independent of the degree of complement dysregulation. With sufficient chronic damage, even if complement normalcy is restored, the likelihood of improving or stabilizing renal function becomes remote and ESRD ensues.</p><p>Factor H autoantibodies (FHAA) have been reported in individuals with C3G; epitope mapping shows that these autoantibodies bind the N-terminus of fH [<a class="bk_pop" href="#mpgn.REF.zhang.2012.265">Zhang et al 2012</a>, <a class="bk_pop" href="#mpgn.REF.blanc.2015.5129">Blanc et al 2015</a>, <a class="bk_pop" href="#mpgn.REF.goodship.2017.539">Goodship et al 2017</a>].</p><p>Factor B autoantibodies (FBAA) have been linked to C3G; however, their role in disease remains unclear [<a class="bk_pop" href="#mpgn.REF.pickering.2013.1079">Pickering et al 2013</a>]. FBAAs were identified in a person with DDD without serum C3NeFs. FBAAs bind to and stabilize C3 convertase, targeting both fB and C3b, enhancing the consumption of C3. C5 convertase formation from C3 convertase is prevented, thus interfering with activation of the terminal complement cascade [<a class="bk_pop" href="#mpgn.REF.strobel.2010.1476">Strobel et al 2010</a>]. Additional studies have identified FBAAs targeting fB and C3b in two individuals with DDD; C3 convertase activity was increased although no C3NeFs were identified [<a class="bk_pop" href="#mpgn.REF.chen.2011.2340">Chen et al 2011</a>].</p><p>As a general rule, C3Nefs, FHAAs, and FBAAs extend the half-life and stabilize C3 convertase, which leads to persistent AP activation in the fluid phase [<a class="bk_pop" href="#mpgn.REF.noris.2015.359">Noris &#x00026; Remuzzi 2015</a>].</p></div></div><div id="mpgn.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>To date, the most striking <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a>-<a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> correlation has been with <i>CFHR</i> fusion genes and the C3GN phenotype (as opposed to the DDD phenotype) (see <a class="figpopup" href="/books/NBK1425/figure/mpgn.F3/?report=objectonly" target="object" rid-figpopup="figmpgnF3" rid-ob="figobmpgnF3">Figure 3</a>).</p></div><div id="mpgn.Nomenclature"><h3>Nomenclature</h3><p><b>C3 glomerulonephritis (C3GN) and dense deposit disease (DDD).</b> Prior to adopting the C3G classification [<a class="bk_pop" href="#mpgn.REF.pickering.2013.1079">Pickering et al 2013</a>], dense deposit disease (DDD) was also described as membranoproliferative glomerulonephritis type 2 (MPGN2). C3 glomerulonephritis (C3GN) was recognized as atypical MPGN1 (Burkholder variant of MPGN1) and atypical MPGN3 (Strife and Anders variant of MPGN3) [<a class="bk_pop" href="#mpgn.REF.dagati.2012.379">D'Agati &#x00026; Bomback 2012</a>, <a class="bk_pop" href="#mpgn.REF.sethi.2016.1278">Sethi et al 2016</a>].</p></div><div id="mpgn.Prevalence"><h3>Prevalence</h3><p>The rarity of C3G makes it difficult to estimate prevalence, although from epidemiologic studies, its prevalence in the USA is estimated at 2-3 per 1,000,000 [<a class="bk_pop" href="#mpgn.REF.smith.2007.2447">Smith et al 2007</a>].</p></div></div><div id="mpgn.Genetically_Related_Allelic_Disorde"><h2 id="_mpgn_Genetically_Related_Allelic_Disorde_">Genetically Related (Allelic) Disorders</h2><p><a class="figpopup" href="/books/NBK1425/table/mpgn.T.allelic_disorders/?report=objectonly" target="object" rid-figpopup="figmpgnTallelicdisorders" rid-ob="figobmpgnTallelicdisorders">Table 2</a> includes other phenotypes caused by pathogenic variants in the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>(s) associated with C3G.</p><div id="mpgn.T.allelic_disorders" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Allelic Disorders</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1425/table/mpgn.T.allelic_disorders/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__mpgn.T.allelic_disorders_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_mpgn.T.allelic_disorders_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene</th><th id="hd_h_mpgn.T.allelic_disorders_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Phenotype&#x000a0;<sup>1</sup></th></tr></thead><tbody><tr><td headers="hd_h_mpgn.T.allelic_disorders_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>C3</i></td><td headers="hd_h_mpgn.T.allelic_disorders_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">C3 deficiency (OMIM <a href="https://www.omim.org/entry/613779" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">613779</a>); <a href="/books/n/gene/husa/">atypical hemolytic-uremic syndrome</a></td></tr><tr><td headers="hd_h_mpgn.T.allelic_disorders_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>CD46</i></td><td headers="hd_h_mpgn.T.allelic_disorders_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/husa/">Atypical hemolytic-uremic syndrome</a></td></tr><tr><td headers="hd_h_mpgn.T.allelic_disorders_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>CFB</i></td><td headers="hd_h_mpgn.T.allelic_disorders_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/husa/">Atypical hemolytic-uremic syndrome</a></td></tr><tr><td headers="hd_h_mpgn.T.allelic_disorders_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>CFH</i></td><td headers="hd_h_mpgn.T.allelic_disorders_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Factor H deficiency (OMIM <a href="https://www.omim.org/entry/609814" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">609814</a>); <a href="/books/n/gene/husa/">atypical hemolytic-uremic syndrome</a>; basal laminar drusen (OMIM <a href="https://www.omim.org/entry/126700" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">126700</a>)</td></tr><tr><td headers="hd_h_mpgn.T.allelic_disorders_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>CFHR1</i></td><td headers="hd_h_mpgn.T.allelic_disorders_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/husa/">Atypical hemolytic uremic syndrome</a></td></tr><tr><td headers="hd_h_mpgn.T.allelic_disorders_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>CFHR5</i></td><td headers="hd_h_mpgn.T.allelic_disorders_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">CFHR5 deficiency (OMIM <a href="https://www.omim.org/entry/614809" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">614809</a>)</td></tr><tr><td headers="hd_h_mpgn.T.allelic_disorders_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>CFI</i></td><td headers="hd_h_mpgn.T.allelic_disorders_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Factor I deficiency (OMIM <a href="https://www.omim.org/entry/610984" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">610984</a>); <a href="/books/n/gene/husa/">atypical hemolytic-uremic syndrome</a>; age-related macular degeneration (OMIM <a href="https://www.omim.org/entry/615439" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">615439</a>)</td></tr><tr><td headers="hd_h_mpgn.T.allelic_disorders_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>DGK&#x00395;</i></td><td headers="hd_h_mpgn.T.allelic_disorders_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Nephrotic syndrome type 7 (OMIM <a href="https://www.omim.org/entry/615008" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">615008</a>); <a href="/books/n/gene/husa/">atypical hemolytic-uremic syndrome</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="mpgn.TF.2.1"><p class="no_margin">See hyperlinked <i>GeneReview</i> or OMIM <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> entry for more information.</p></div></dd></dl></div></div></div></div><div id="mpgn.Differential_Diagnosis"><h2 id="_mpgn_Differential_Diagnosis_">Differential Diagnosis</h2><div id="mpgn.T.disorders_to_consider_in_the_diff" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p>Disorders to Consider in the Differential Diagnosis of C3G</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1425/table/mpgn.T.disorders_to_consider_in_the_diff/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__mpgn.T.disorders_to_consider_in_the_diff_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_mpgn.T.disorders_to_consider_in_the_diff_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_mpgn.T.disorders_to_consider_in_the_diff_1_1_1_1" style="text-align:left;vertical-align:middle;">Disorder</th><th id="hd_h_mpgn.T.disorders_to_consider_in_the_diff_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_mpgn.T.disorders_to_consider_in_the_diff_1_1_1_2" style="text-align:left;vertical-align:middle;">Gene(s)</th><th id="hd_h_mpgn.T.disorders_to_consider_in_the_diff_1_1_1_3" rowspan="2" scope="col" colspan="1" headers="hd_h_mpgn.T.disorders_to_consider_in_the_diff_1_1_1_3" style="text-align:left;vertical-align:middle;">MOI</th><th id="hd_h_mpgn.T.disorders_to_consider_in_the_diff_1_1_1_4" colspan="2" scope="colgroup" rowspan="1" style="text-align:center;vertical-align:middle;">Clinical Features of This Disorder</th></tr><tr><th headers="hd_h_mpgn.T.disorders_to_consider_in_the_diff_1_1_1_4" id="hd_h_mpgn.T.disorders_to_consider_in_the_diff_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Overlapping w/C3G</th><th headers="hd_h_mpgn.T.disorders_to_consider_in_the_diff_1_1_1_4" id="hd_h_mpgn.T.disorders_to_consider_in_the_diff_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Distinguishing from C3G</th></tr></thead><tbody><tr><td headers="hd_h_mpgn.T.disorders_to_consider_in_the_diff_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Post-infectious glomerulonephritis&#x000a0;<sup>1</sup></td><td headers="hd_h_mpgn.T.disorders_to_consider_in_the_diff_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">NA</td><td headers="hd_h_mpgn.T.disorders_to_consider_in_the_diff_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Acquired</td><td headers="hd_h_mpgn.T.disorders_to_consider_in_the_diff_1_1_1_4 hd_h_mpgn.T.disorders_to_consider_in_the_diff_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hematuria, proteinuria, nephritic syndrome, edema, &#x02193; serum C3, C3 glomerular deposition, subepithelial hump-like deposits</td><td headers="hd_h_mpgn.T.disorders_to_consider_in_the_diff_1_1_1_4 hd_h_mpgn.T.disorders_to_consider_in_the_diff_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Post-infection (throat or skin) often due to Group A hemolytic <i>streptococcus</i> bacterium; &#x02193; levels of C3 resolve w/in 3 mos; glomerular codeposition of C3 &#x00026; IgG</td></tr><tr><td headers="hd_h_mpgn.T.disorders_to_consider_in_the_diff_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Immune-complex MPGN&#x000a0;<sup>2</sup></td><td headers="hd_h_mpgn.T.disorders_to_consider_in_the_diff_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">NA</td><td headers="hd_h_mpgn.T.disorders_to_consider_in_the_diff_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Acquired</td><td headers="hd_h_mpgn.T.disorders_to_consider_in_the_diff_1_1_1_4 hd_h_mpgn.T.disorders_to_consider_in_the_diff_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hematuria, proteinuria, C3 deposits, subendothelial &#x00026; subepithelial deposits, progressive disease</td><td headers="hd_h_mpgn.T.disorders_to_consider_in_the_diff_1_1_1_4 hd_h_mpgn.T.disorders_to_consider_in_the_diff_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Immune complex-mediated, often low complement C4 levels; codeposition of C3 &#x00026; IgG/IgM/C1q/C4 on IF</td></tr><tr><td headers="hd_h_mpgn.T.disorders_to_consider_in_the_diff_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Juvenile acute non-proliferative glomerulonephritis&#x000a0;<sup>3</sup></td><td headers="hd_h_mpgn.T.disorders_to_consider_in_the_diff_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">NA</td><td headers="hd_h_mpgn.T.disorders_to_consider_in_the_diff_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Acquired</td><td headers="hd_h_mpgn.T.disorders_to_consider_in_the_diff_1_1_1_4 hd_h_mpgn.T.disorders_to_consider_in_the_diff_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Mesangial cell proliferation, subepithelial deposits on EM</td><td headers="hd_h_mpgn.T.disorders_to_consider_in_the_diff_1_1_1_4 hd_h_mpgn.T.disorders_to_consider_in_the_diff_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">C3 levels typically remaining in lower limits of normal</td></tr><tr><td headers="hd_h_mpgn.T.disorders_to_consider_in_the_diff_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Familial lecithin-cholesterol acyltransferase deficiency&#x000a0;<sup>4</sup></td><td headers="hd_h_mpgn.T.disorders_to_consider_in_the_diff_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>LCAT</i></td><td headers="hd_h_mpgn.T.disorders_to_consider_in_the_diff_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_mpgn.T.disorders_to_consider_in_the_diff_1_1_1_4 hd_h_mpgn.T.disorders_to_consider_in_the_diff_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">ESRD, glomerular pattern of IF similar to dense deposit disease</td><td headers="hd_h_mpgn.T.disorders_to_consider_in_the_diff_1_1_1_4 hd_h_mpgn.T.disorders_to_consider_in_the_diff_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Abnormal lipoprotein (lipoprotein X); corneal opacities; normochromic anemia; capillary endothelial damage; cross-striated &#x00026; vacuole structures</td></tr><tr><td headers="hd_h_mpgn.T.disorders_to_consider_in_the_diff_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Partial lipodystrophy&#x000a0;<sup>5</sup></td><td headers="hd_h_mpgn.T.disorders_to_consider_in_the_diff_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Several genes</td><td headers="hd_h_mpgn.T.disorders_to_consider_in_the_diff_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD/AR</td><td headers="hd_h_mpgn.T.disorders_to_consider_in_the_diff_1_1_1_4 hd_h_mpgn.T.disorders_to_consider_in_the_diff_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Loss of subcutaneous fat in upper half of the body</td><td headers="hd_h_mpgn.T.disorders_to_consider_in_the_diff_1_1_1_4 hd_h_mpgn.T.disorders_to_consider_in_the_diff_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">No renal disease; no dysregulation of complement alternative pathway</td></tr><tr><td headers="hd_h_mpgn.T.disorders_to_consider_in_the_diff_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Age-related macular degeneration&#x000a0;<sup>6</sup></td><td headers="hd_h_mpgn.T.disorders_to_consider_in_the_diff_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Many genes</td><td headers="hd_h_mpgn.T.disorders_to_consider_in_the_diff_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_mpgn.T.disorders_to_consider_in_the_diff_1_1_1_4 hd_h_mpgn.T.disorders_to_consider_in_the_diff_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Drusen</td><td headers="hd_h_mpgn.T.disorders_to_consider_in_the_diff_1_1_1_4 hd_h_mpgn.T.disorders_to_consider_in_the_diff_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Absence of renal disease</td></tr><tr><td headers="hd_h_mpgn.T.disorders_to_consider_in_the_diff_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Malattia Leventinese &#x00026; Doyne honeycomb retinal dystrophy&#x000a0;<sup>7</sup></td><td headers="hd_h_mpgn.T.disorders_to_consider_in_the_diff_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>EFEMP1</i></td><td headers="hd_h_mpgn.T.disorders_to_consider_in_the_diff_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_mpgn.T.disorders_to_consider_in_the_diff_1_1_1_4 hd_h_mpgn.T.disorders_to_consider_in_the_diff_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Drusen</td><td headers="hd_h_mpgn.T.disorders_to_consider_in_the_diff_1_1_1_4 hd_h_mpgn.T.disorders_to_consider_in_the_diff_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Absence of renal disease</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">AD = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a>; AR = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>; EM = electron microscopy; IF = immunofluorescence; MOI = <a class="def" href="/books/n/gene/glossary/def-item/mode-of-inheritance/">mode of inheritance</a>; MPGN = membranoproliferative glomerulonephritis</p></div></dd><dt>1. </dt><dd><div id="mpgn.TF.3.1"><p class="no_margin"><a class="bk_pop" href="#mpgn.REF.sotsiou.2001.68">Sotsiou [2001]</a>, <a class="bk_pop" href="#mpgn.REF.kambham.2012.338">Kambham [2012]</a>, <a class="bk_pop" href="#mpgn.REF.sethi.2013.293">Sethi et al [2013]</a>, <a class="bk_pop" href="#mpgn.REF.khalighi.2016.397">Khalighi et al [2016]</a></p></div></dd><dt>2. </dt><dd><div id="mpgn.TF.3.2"><p class="no_margin"><a class="bk_pop" href="#mpgn.REF.sethi.2011.341">Sethi &#x00026; Fervenza [2011]</a>, <a class="bk_pop" href="#mpgn.REF.noris.2015.359">Noris &#x00026; Remuzzi [2015]</a>, <a class="bk_pop" href="#mpgn.REF.nester.2016.241">Nester &#x00026; Smith [2016]</a></p></div></dd><dt>3. </dt><dd><div id="mpgn.TF.3.3"><p class="no_margin"><a class="bk_pop" href="#mpgn.REF.west.2000.786">West et al [2000]</a>, <a class="bk_pop" href="#mpgn.REF.fujita.2007.1957">Fujita et al [2007]</a></p></div></dd><dt>4. </dt><dd><div id="mpgn.TF.3.4"><p class="no_margin"><a class="bk_pop" href="#mpgn.REF.sessa.2001.268">Sessa et al [2001]</a>, <a class="bk_pop" href="#mpgn.REF.ossoli.2015.405">Ossoli et al [2015]</a></p></div></dd><dt>5. </dt><dd><div id="mpgn.TF.3.5"><p class="no_margin"><a class="bk_pop" href="#mpgn.REF.eisinger.1972.343">Eisinger et al [1972]</a>, <a class="bk_pop" href="#mpgn.REF.mathieson.1997.1804">Mathieson &#x00026; Peters [1997]</a>, <a class="bk_pop" href="#mpgn.REF.licht.2008">Licht &#x00026; Mengel [2008]</a>, <a class="bk_pop" href="#mpgn.REF.licht.2009.271">Licht &#x00026; Fremeaux-Bacchi [2009]</a>, <a class="bk_pop" href="#mpgn.REF.gale.2014">Gale &#x00026; Owen-Casey [2014]</a></p></div></dd><dt>6. </dt><dd><div id="mpgn.TF.3.6"><p class="no_margin"><a class="bk_pop" href="#mpgn.REF.hageman.2005.7227">Hageman et al [2005]</a> , <a class="bk_pop" href="#mpgn.REF.licht.2008">Licht &#x00026; Mengel [2008]</a>, <a class="bk_pop" href="#mpgn.REF.licht.2009.271">Licht &#x00026; Fremeaux-Bacchi [2009]</a>, <a class="bk_pop" href="#mpgn.REF.gale.2014">Gale &#x00026; Owen-Casey [2014]</a></p></div></dd><dt>7. </dt><dd><div id="mpgn.TF.3.7"><p class="no_margin"><a class="bk_pop" href="#mpgn.REF.stone.1999.199">Stone et al [1999]</a>, <a class="bk_pop" href="#mpgn.REF.mullins.2001.390">Mullins et al [2001]</a>, <a class="bk_pop" href="#mpgn.REF.sohn.2015.48">Sohn et al [2015]</a>, <a class="bk_pop" href="#mpgn.REF.hulleman.2016.153">Hulleman [2016]</a>, <a class="bk_pop" href="#mpgn.REF.vaclavik.2016">Vaclavik &#x00026; Munier [2016]</a></p></div></dd></dl></div></div></div></div><div id="mpgn.Management"><h2 id="_mpgn_Management_">Management</h2><div id="mpgn.Evaluations_Following_Initial_Diagn"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual diagnosed with C3G, the following evaluations are recommended if they have not already been completed:</p><ul><li class="half_rhythm"><div>Evaluate the complement system by measuring serum/plasma concentrations of C3, C3c, C3d, C4, C5, fB, Ba, Bb, fH, fI, properdin, and s(C5b-9).</div></li><li class="half_rhythm"><div>Quantitate the degree of complement function by measuring CH50 and APH50.</div></li><li class="half_rhythm"><div>Measure autoantibodies including C3NeFs, C4NeFs, C5NeFs, FHAA, and FBAA.</div></li><li class="half_rhythm"><div>Establish the extent of renal disease by measuring serum creatinine concentration, and monitor creatinine clearance, proteinuria, and hematuria.</div></li><li class="half_rhythm"><div>Quantitate the degree of chronic renal damage by renal biopsy.</div></li><li class="half_rhythm"><div>Obtain a baseline ophthalmologic examination.</div></li><li class="half_rhythm"><div>Consult with a clinical geneticist and/or genetic counselor.</div></li></ul></div><div id="mpgn.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p>Currently, there are no therapeutic agents specifically designed to target the underlying complement dysregulation that occurs in individuals with C3G. Nonspecific therapies are most commonly used.</p><p><b>Nonspecific therapies</b> have been shown to be effective in numerous chronic glomerular diseases. The judicious use of these agents along with optimal blood pressure control is of benefit in individuals with C3G.</p><ul><li class="half_rhythm"><div><b>Angiotensin-converting enzyme inhibitors and angiotensin II type-1 receptor blockers</b> decrease proteinuria in many glomerular diseases and slow the progression to renal failure [<a class="bk_pop" href="#mpgn.REF.licht.2006.42">Licht et al 2006</a>, <a class="bk_pop" href="#mpgn.REF.lu.2012.773">Lu et al 2012</a>, <a class="bk_pop" href="#mpgn.REF.nester.2016.241">Nester &#x00026; Smith 2016</a>, <a class="bk_pop" href="#mpgn.REF.riedl.2017.43">Riedl et al 2017</a>]. A retrospective study found that the combination of angiotensin blockers and immunosuppressants (steroids) is more effective than each therapy alone in preventing the development of renal failure [<a class="bk_pop" href="#mpgn.REF.nasr.2009.22">Nasr et al 2009</a>, <a class="bk_pop" href="#mpgn.REF.nester.2013b.231">Nester &#x00026; Smith 2013b</a>, <a class="bk_pop" href="#mpgn.REF.thomas.2014.339">Thomas et al 2014</a>, <a class="bk_pop" href="#mpgn.REF.cook.2017.248">Cook 2017</a>].</div></li><li class="half_rhythm"><div><b>Lipid-lowering agents,</b> and in particular hydroxymethylglutaryl coenzyme A reductase inhibitors, may delay progression of renal disease as well as correct endothelial cell dysfunction and alter long-term atherosclerotic risks in the presence of hyperlipidemia [<a class="bk_pop" href="#mpgn.REF.nester.2013b.231">Nester &#x00026; Smith 2013b</a>, <a class="bk_pop" href="#mpgn.REF.thomas.2014.339">Thomas et al 2014</a>]. These agents are not widely used in children.</div></li><li class="half_rhythm"><div><b>Complement inhibition</b> with a terminal pathway blocker may alter disease course. Eculizumab is a recombinant humanized monoclonal antibody that targets C5. It blocks cleavage of C5 by C5 convertase, thereby having two effects: (1) an anti-inflammatory effect caused by preventing the release of C5a, a potent anaphylatoxin; and (2) an anticomplement effect caused by preventing formation of the terminal complement complex (see <a class="figpopup" href="/books/NBK1425/figure/mpgn.F4/?report=objectonly" target="object" rid-figpopup="figmpgnF4" rid-ob="figobmpgnF4">Figure 4</a>). Reports of its use in individuals with C3G have demonstrated limited success [ClinicalTrials.gov <a href="https://clinicaltrials.gov/ct2/results?cond=&#x00026;term=NCT00838513" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NCT00838513</a>, <a class="bk_pop" href="#mpgn.REF.bomback.2012.748">Bomback et al 2012</a>].</div><ul><li class="half_rhythm"><div>Individuals with C3G treated with eculizumab have not produced a uniform response [<a class="bk_pop" href="#mpgn.REF.noris.2015.359">Noris &#x00026; Remuzzi 2015</a>].</div></li><li class="half_rhythm"><div>Early administration of eculizumab prior to sclerotic tissue formation provides better results, reduces proteinuria, and improves kidney health [<a class="bk_pop" href="#mpgn.REF.vivarelli.2014.472">Vivarelli &#x00026; Emma 2014</a>]; however, success of this therapeutic is limited in C3G because proximal complement control is not restored (see <a class="figpopup" href="/books/NBK1425/figure/mpgn.F4/?report=objectonly" target="object" rid-figpopup="figmpgnF4" rid-ob="figobmpgnF4">Figure 4</a>).</div></li></ul></li></ul><p><b>Renal allografts.</b> When end-stage renal disease (ESRD) develops, treatment options are limited to dialysis or transplantation. When an individual with C3G elects to undergo a renal transplant, it is important to recognize that C3G recurs in nearly all grafts and is the predominant cause of graft failure in 50%-90% of transplant recipients [<a class="bk_pop" href="#mpgn.REF.appel.2005.1392">Appel et al 2005</a>, <a class="bk_pop" href="#mpgn.REF.angelo.2011.291">Angelo et al 2011</a>, <a class="bk_pop" href="#mpgn.REF.lu.2012.773">Lu et al 2012</a>, <a class="bk_pop" href="#mpgn.REF.servais.2012.454">Servais et al 2012</a>, <a class="bk_pop" href="#mpgn.REF.zand.2014.1110">Zand et al 2014</a>, <a class="bk_pop" href="#mpgn.REF.salvadori.2016.632">Salvadori &#x00026; Bertoni 2016</a>, <a class="bk_pop" href="#mpgn.REF.goodship.2017.539">Goodship et al 2017</a>]. Data suggesting that any therapeutic interventions reverse this course are limited, although isolated reports have described the use of plasmapheresis, which appears to be of equivocal benefit [<a class="bk_pop" href="#mpgn.REF.fremeauxbacchi.1994.811">Fremeaux-Bacchi et al 1994</a>, <a class="bk_pop" href="#mpgn.REF.kurtz.2002.135">Kurtz &#x00026; Schlueter 2002</a>]. A thorough complement and genetic evaluation of the transplant recipient is recommended pre-transplantation as results may inform post-transplant care. In addition, a genetic assessment is recommended for relatives being considered as kidney donors.</p></div><div id="mpgn.Prevention_of_Primary_Manifestation"><h3>Prevention of Primary Manifestations</h3><p>Most treatments for C3G are ineffective; however, plasma replacement therapy in individuals with pathogenic variants in <i>CFH</i> has been reported by some authors to be effective in controlling complement activation and slowing progression of ESRD [<a class="bk_pop" href="#mpgn.REF.licht.2006.42">Licht et al 2006</a>]. Other authors report that the benefit of plasma exchange is inconsistent in reducing progression to ESRD [<a class="bk_pop" href="#mpgn.REF.kurtz.2002.135">Kurtz &#x00026; Schlueter 2002</a>, <a class="bk_pop" href="#mpgn.REF.mccaughan.2012.1046">McCaughan et al 2012</a>, <a class="bk_pop" href="#mpgn.REF.servais.2013.185">Servais et al 2013</a>, <a class="bk_pop" href="#mpgn.REF.thomas.2014.339">Thomas et al 2014</a>].</p></div><div id="mpgn.Surveillance"><h3>Surveillance</h3><p>The following are appropriate:</p><ul><li class="half_rhythm"><div>Close monitoring of renal function by a nephrologist with familiarity with the C3G disease spectrum</div><div>Note: Frequency of follow up and testing required is determined by the degree of renal dysfunction.</div></li><li class="half_rhythm"><div>Complete biannual assessment of the complement pathway</div></li><li class="half_rhythm"><div>Periodic eye examinations to evaluate the fundus</div></li></ul></div><div id="mpgn.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>There are very few <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> cases of C3G. However, if the family history is positive for renal disease, it is appropriate to evaluate apparently asymptomatic sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> and at-risk relatives to identify those who would benefit from periodic observation and continued follow up for management of renal disease.</p><p>Evaluations can include:</p><ul><li class="half_rhythm"><div>Molecular genetic testing if the pathogenic variants in the family are known. Penetrance rates, however, are not known.</div></li><li class="half_rhythm"><div>Urinalysis</div></li><li class="half_rhythm"><div>Comprehensive analysis of the complement system if the pathogenic variants in the family are not known.</div></li></ul><p>See <a href="#mpgn.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="mpgn.Pregnancy_Management"><h3>Pregnancy Management</h3><p>Chronic kidney disease does not preclude pregnancy, but any pregnancy in a woman with C3G should be followed by a nephrologist and obstetrician with expertise in caring for pregnant women with chronic kidney disease [<a class="bk_pop" href="#mpgn.REF.nava.2017.877">Nava et al 2017</a>, <a class="bk_pop" href="#mpgn.REF.piccoli.2018.66">Piccoli et al 2018</a>].</p><p>See <a href="http://www.mothertobaby.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">MotherToBaby</a> for further information on medication use during pregnancy.</p></div><div id="mpgn.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Numerous anti-complement therapies are entering clinical trials for individuals with C3G. These trials are registered under <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a>.</p><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EU Clinical Trials Register</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions.</p></div></div><div id="mpgn.Genetic_Counseling"><h2 id="_mpgn_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="mpgn.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>C3G is a complex genetic disorder that is rarely inherited in a simple mendelian fashion. In most persons with C3G, inheritance is complex and incompletely understood. For these reasons, <a class="def" href="/books/n/gene/glossary/def-item/recurrence-risk/">recurrence risk</a> to family members is not known but likely very low.</p><ul><li class="half_rhythm"><div>In persons with C3G in whom two pathogenic variants can be identified<i>,</i> inheritance is <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>.</div></li><li class="half_rhythm"><div>Multiple <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> persons within a single nuclear family are only reported occasionally; in these instances, parental <a class="def" href="/books/n/gene/glossary/def-item/consanguinity/">consanguinity</a> is common [<a class="bk_pop" href="#mpgn.REF.licht.2006.42">Licht et al 2006</a>].</div></li><li class="half_rhythm"><div>Autosomal dominant cases of C3G are reported in association with CFHR hybrid fusion proteins (see <a class="figpopup" href="/books/NBK1425/figure/mpgn.F3/?report=objectonly" target="object" rid-figpopup="figmpgnF3" rid-ob="figobmpgnF3">Figure 3</a>).</div></li></ul></div><div id="mpgn.Autosomal_Recessive_C3G"><h3>Autosomal Recessive C3G</h3><div id="mpgn.Risk_to_Family_Members"><h4>Risk to Family Members</h4><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The parents of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> child are obligate heterozygotes (i.e., carriers of one <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>).</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are asymptomatic and not at risk of developing the disorder.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier.</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The offspring of an individual with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> C3G are obligate heterozygotes (carriers) for a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p><p><b>Other family members.</b> Each sib of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents is at a 50% risk of being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> of a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p></div><div id="mpgn.Carrier_Heterozygote_Detection"><h4>Carrier (Heterozygote) Detection</h4><p>Carrier testing for at-risk relatives requires prior identification of the pathogenic variants in the family.</p></div></div><div id="mpgn.Autosomal_Dominant_C3G__Risk_to_Fam"><h3>Autosomal Dominant C3G &#x02013; Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>Few individuals (&#x0003c;1%) diagnosed with C3G have an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent.</div></li><li class="half_rhythm"><div>Because <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> cases (i.e., a single occurrence in a family) have not been evaluated sufficiently to determine if the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> occurred <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a>, the proportion of C3G caused by a <i>de novo</i> pathogenic variant is unknown.</div><ul><li class="half_rhythm"><div>Molecular genetic testing is recommended for the parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</div></li><li class="half_rhythm"><div>If the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> found in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> cannot be detected in leukocyte DNA of either parent, possible explanations include a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> pathogenic variant in the proband or <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> in a parent. Though theoretically possible, no instances of germline mosaicism have been reported.</div></li></ul></li><li class="half_rhythm"><div>The family history of some individuals diagnosed with C3G may appear to be negative because of failure to recognize the disorder in family members, reduced <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a>, early death of the parent before the onset of symptoms, or late onset of the disease in the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent. Therefore, an apparently negative family history cannot be confirmed unless appropriate clinical evaluation and/or <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> has been performed on the parents of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The risk to the sibs of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> depends on the genetic status of the proband's parents.</div></li><li class="half_rhythm"><div>If a parent of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, the risk to the sibs of inheriting the genetic variant is 50%. However, there is reduced <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> in families [<a class="bk_pop" href="#mpgn.REF.xiao.2014.465">Xiao et al 2014</a>].</div></li><li class="half_rhythm"><div>If the parents have been tested for the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> identified in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> and:</div><ul><li class="half_rhythm"><div>A parent of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> has the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, the risk to the sibs of inheriting the variant is 50%.</div></li><li class="half_rhythm"><div>If the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> found in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> cannot be detected in the leukocyte DNA of either parent, the risk to sibs is presumed to be slightly greater than that of the general population (though still &#x0003c;1%) because of the theoretic possibility of parental <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a>.</div></li></ul></li><li class="half_rhythm"><div>If the parents have not been tested for the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> but are clinically unaffected, the risk to the sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> is extremely low. The sibs of a proband with clinically unaffected parents are still at increased risk for C3G because of the possibility of reduced <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> in a parent or the theoretic possibility of parental <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a>.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Each child of an individual with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> C3G has a 50% chance of inheriting the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>; however, <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> is extremely variable [<a class="bk_pop" href="#mpgn.REF.xiao.2014.465">Xiao et al 2014</a>].</p><p><b>Other family members.</b> The risk to other family members depends on the status of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents: if a parent has the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, his or her family members may be at risk.</p></div><div id="mpgn.Other_Etiologies__Risk_to_Family_Me"><h3>Other Etiologies &#x02013; Risk to Family Members</h3><p><b>Parents, sibs, and offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The risk to the family members of a proband who does not have identified pathogenic variants or a family history consistent with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> or dominant inheritance is low.</p></div><div id="mpgn.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#mpgn.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</a> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p><p>Other autoimmune diseases, in particular diabetes mellitus type 1 and <a href="/books/n/gene/celiac/">celiac disease</a>, are diagnosed more frequently in families with C3G (16% of families) than would be expected based on estimates in the general population [<a class="bk_pop" href="#mpgn.REF.smith.2007.2447">Smith et al 2007</a>, <a class="bk_pop" href="#mpgn.REF.lu.2012.773">Lu et al 2012</a>, <a class="bk_pop" href="#mpgn.REF.barbour.2013a.1685">Barbour et al 2013a</a>, <a class="bk_pop" href="#mpgn.REF.thomas.2014.339">Thomas et al 2014</a>].</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk, clarification of <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status, and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, are carriers, or are at risk of being carriers.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="mpgn.Prenatal_Testing_and_Preimplantatio"><h3>Prenatal Testing and Preimplantation Genetic Testing</h3><p>Once the pathogenic variants have been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-testing/">preimplantation genetic testing</a> are possible.</p><p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. While most centers would consider decisions regarding prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p></div></div><div id="mpgn.Resources"><h2 id="_mpgn_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>Kidneeds</b></div><div><i>Dedicated to the study of Dense Deposit Disease</i></div><div>Cedar Rapids IA </div><div><b>Email:</b> kidneedsMPGN@yahoo.com</div><div><a href="http://www.healthcare.uiowa.edu/kidneeds/index.htm" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.healthcare.uiowa.edu/kidneeds</a></div></li><li class="half_rhythm"><div><b>Kidney Foundation of Canada</b></div><div>310-5160 Decarie Blvd.</div><div>Montreal Ontario H3X 2H9 </div><div>Canada</div><div><b>Phone:</b> 800-361-7494 (toll-free); 514-369-4806</div><div><b>Fax:</b> 514-369-2472 </div><div><b>Email:</b> info@kidney.ca</div><div><a href="http://www.kidney.on.ca" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.kidney.ca</a></div></li><li class="half_rhythm"><div><b>Medline Plus</b></div><div><a href="http://www.nlm.nih.gov/medlineplus/ency/article/000484.htm" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Glomerulonephritis</a></div></li><li class="half_rhythm"><div><b>National Kidney Foundation (NKF)</b></div><div>30 East 33rd Street</div><div>New York NY 10016</div><div><b>Phone:</b> 800-622-9010 (toll-free); 212-889-2210</div><div><b>Email:</b> info@kidney.org</div><div><a href="http://www.kidney.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.kidney.org</a></div></li></ul></div><div id="mpgn.Molecular_Genetics"><h2 id="_mpgn_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="mpgn.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>C3 Glomerulopathy: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1425/table/mpgn.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__mpgn.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_mpgn.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_mpgn.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_mpgn.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_mpgn.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_mpgn.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_mpgn.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_mpgn.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/718" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>C3</i></a></td><td headers="hd_b_mpgn.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=718" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">19p13<wbr style="display:inline-block"></wbr>​.3</a></td><td headers="hd_b_mpgn.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P01024" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Complement C3</a></td><td headers="hd_b_mpgn.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://databases.lovd.nl/shared/genes/C3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">C3 database</a><br /><a href="http://structure.bmc.lu.se/idbase/C3base/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">C3base: Mutation registry for C3 deficiency</a></td><td headers="hd_b_mpgn.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=C3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">C3</a></td><td headers="hd_b_mpgn.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=C3[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">C3</a></td></tr><tr><td headers="hd_b_mpgn.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/4179" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>CD46</i></a></td><td headers="hd_b_mpgn.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=4179" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">1q32<wbr style="display:inline-block"></wbr>​.2</a></td><td headers="hd_b_mpgn.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P15529" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Membrane cofactor protein</a></td><td headers="hd_b_mpgn.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://databases.lovd.nl/shared/genes/CD46" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">CD46 database</a></td><td headers="hd_b_mpgn.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=CD46" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">CD46</a></td><td headers="hd_b_mpgn.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=CD46[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">CD46</a></td></tr><tr><td headers="hd_b_mpgn.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/629" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>CFB</i></a></td><td headers="hd_b_mpgn.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=629" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">6p21<wbr style="display:inline-block"></wbr>​.33</a></td><td headers="hd_b_mpgn.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P00751" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Complement factor B</a></td><td headers="hd_b_mpgn.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://databases.lovd.nl/shared/genes/CFB" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">CFB database</a></td><td headers="hd_b_mpgn.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=CFB" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">CFB</a></td><td headers="hd_b_mpgn.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=CFB[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">CFB</a></td></tr><tr><td headers="hd_b_mpgn.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/3075" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>CFH</i></a></td><td headers="hd_b_mpgn.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=3075" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">1q31<wbr style="display:inline-block"></wbr>​.3</a></td><td headers="hd_b_mpgn.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P08603" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Complement factor H</a></td><td headers="hd_b_mpgn.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://structure.bmc.lu.se/idbase/CFHbase/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">CFHbase: Mutation registry for Factor H deficiency (previously known as HF1base)</a></td><td headers="hd_b_mpgn.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=CFH" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">CFH</a></td><td headers="hd_b_mpgn.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=CFH[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">CFH</a></td></tr><tr><td headers="hd_b_mpgn.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/3078" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>CFHR1</i></a></td><td headers="hd_b_mpgn.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=3078" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">1q31<wbr style="display:inline-block"></wbr>​.3</a></td><td headers="hd_b_mpgn.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q03591" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Complement factor H-related protein 1</a></td><td headers="hd_b_mpgn.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://databases.lovd.nl/shared/genes/CFHR1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">CFHR1 database</a></td><td headers="hd_b_mpgn.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=CFHR1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">CFHR1</a></td><td headers="hd_b_mpgn.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=CFHR1[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">CFHR1</a></td></tr><tr><td headers="hd_b_mpgn.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/81494" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>CFHR5</i></a></td><td headers="hd_b_mpgn.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=81494" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">1q31<wbr style="display:inline-block"></wbr>​.3</a></td><td headers="hd_b_mpgn.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q9BXR6" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Complement factor H-related protein 5</a></td><td headers="hd_b_mpgn.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_b_mpgn.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=CFHR5" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">CFHR5</a></td><td headers="hd_b_mpgn.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=CFHR5[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">CFHR5</a></td></tr><tr><td headers="hd_b_mpgn.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/3426" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>CFI</i></a></td><td headers="hd_b_mpgn.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=3426" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">4q25</a></td><td headers="hd_b_mpgn.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P05156" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Complement factor I</a></td><td headers="hd_b_mpgn.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://databases.lovd.nl/shared/genes/CFI" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">CFI database</a><br /><a href="http://structure.bmc.lu.se/idbase/CFIbase/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">CFIbase: Mutation registry for Factor I deficiency (previously known as IFbase)</a></td><td headers="hd_b_mpgn.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=CFI" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">CFI</a></td><td headers="hd_b_mpgn.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=CFI[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">CFI</a></td></tr><tr><td headers="hd_b_mpgn.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/8526" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>DGKE</i></a></td><td headers="hd_b_mpgn.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=8526" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">17q22</a></td><td headers="hd_b_mpgn.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P52429" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Diacylglycerol kinase epsilon</a></td><td headers="hd_b_mpgn.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_b_mpgn.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=DGKE" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">DGKE</a></td><td headers="hd_b_mpgn.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=DGKE[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">DGKE</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="mpgn.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="mpgn.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for C3 Glomerulopathy (<a href="/omim/120700,120920,134370,134371,138470,217030,601440,608593,609814,610984,613779,615008" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1425/table/mpgn.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__mpgn.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/120700" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">120700</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">COMPLEMENT COMPONENT 3; C3</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/120920" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">120920</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CD46 ANTIGEN; CD46</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/134370" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">134370</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">COMPLEMENT FACTOR H; CFH</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/134371" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">134371</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">COMPLEMENT FACTOR H-RELATED 1; CFHR1</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/138470" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">138470</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">COMPLEMENT FACTOR B; CFB</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/217030" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">217030</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">COMPLEMENT FACTOR I; CFI</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/601440" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">601440</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">DIACYLGLYCEROL KINASE, EPSILON, 64-KD; DGKE</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/608593" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">608593</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">COMPLEMENT FACTOR H-RELATED 5; CFHR5</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/609814" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">609814</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">COMPLEMENT FACTOR H DEFICIENCY; CFHD</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/610984" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">610984</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">COMPLEMENT FACTOR I DEFICIENCY; CFID</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/613779" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">613779</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">COMPLEMENT COMPONENT 3 DEFICIENCY, AUTOSOMAL RECESSIVE; C3D</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/615008" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">615008</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NEPHROTIC SYNDROME, TYPE 7; NPHS7</td></tr></tbody></table></div></div><div id="mpgn.Molecular_Pathogenesis"><h3>Molecular Pathogenesis</h3><p>The complement system, composed of the classic pathway and the alternate pathway, is a component of the immune system that enhances the function of antibodies and phagocytes. C3 glomerulopathy (C3G) is caused by uncontrolled activation of the complement alternative pathway.</p><p>With the exception of <i>DGKE</i>, all the genes discussed in association with C3G encode proteins in the complement system. C3 and CFB are integral to complement activation and together form C3bBb, a C3 convertase that amplifies the initial complement response, and C3bBbC3b, a C5 convertase that cleaves C5 into C5a and C5b to trigger the terminal pathway. CD46, CFH, CFHR1, CFHR5, and CFI are complement regulators. The role of <i>DGKE</i> in complement activation, although minimal, is believed to be essential in normal podocyte function.</p><p>Familial cases of C3G are uncommon and when identified are most often highly penetrant <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> copy number variants involving the <i>CFHR1-5</i> genes (see <a class="figpopup" href="/books/NBK1425/figure/mpgn.F3/?report=objectonly" target="object" rid-figpopup="figmpgnF3" rid-ob="figobmpgnF3">Figure 3</a>), <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> variants that lead to <i>CFH</i> deficiency, or heterozygous <a class="def" href="/books/n/gene/glossary/def-item/gain-of-function/">gain-of-function</a> variants in <i>C3</i>. Common to all of these variants is an impact on the regulation of the AP in the fluid phase [<a class="bk_pop" href="#mpgn.REF.noris.2017.447">Noris &#x00026; Remuzzi 2017</a>].</p><p>Since C3G is rarely inherited in a simple mendelian fashion, the study of rare variants and haplotypes associated with disease is important.</p><p>Several studies have shown that some common variants in complement genes are also associated with C3G and increase the odds ratio of developing disease [<a class="bk_pop" href="#mpgn.REF.abreraabeleda.2011.1551">Abrera-Abeleda et al 2011</a>, <a class="bk_pop" href="#mpgn.REF.kobayashi.2017.13">Kobayashi et al 2017</a>]. While the identification of common variants that are C3G "risk alleles" <i>cannot</i> be used to direct clinical care, the identification of rare variants in complement genes does affect patient care, especially in the context of a comprehensive assessment of complement function, which includes plasma levels of complement proteins and their split products, assays for autoantibodies, and tests of overall complement activity. For more detailed information, see <a class="bk_pop" href="#mpgn.REF.osborne.2018.2464">Osborne et al [2018]</a>.</p><div id="mpgn.C3"><h4><i>C3</i></h4><p><b>Gene structure.</b>
<i>C3</i> comprises 41 exons that encode complement C3, which has a molecular weight of 176 kd. The mature protein forms a beta chain and an alpha chain. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK1425/#mpgn.molgen.TA">Table A</a>.</p><p><b>Benign variants.</b> Several <i>C3</i> variants (some of which are common in the population) are associated with C3G and define an at-risk haplotype [<a class="bk_pop" href="#mpgn.REF.hageman.2005.7227">Hageman et al 2005</a>, <a class="bk_pop" href="#mpgn.REF.smith.2007.2447">Smith et al 2007</a>, <a class="bk_pop" href="#mpgn.REF.fremeauxbacchi.2008.2093">Fremeaux-Bacchi et al 2008</a>, <a class="bk_pop" href="#mpgn.REF.abreraabeleda.2011.1551">Abrera-Abeleda et al 2011</a>, <a class="bk_pop" href="#mpgn.REF.iatropoulos.2016.131">Iatropoulos et al 2016</a>, <a class="bk_pop" href="#mpgn.REF.riedl.2017.43">Riedl et al 2017</a>, <a class="bk_pop" href="#mpgn.REF.osborne.2018.2464">Osborne et al 2018</a>].</p><p><b>Pathogenic variants.</b> Pathogenic variants and their location are shown in <a class="figpopup" href="/books/NBK1425/table/mpgn.T.c3_pathogenic_variants_discussed/?report=objectonly" target="object" rid-figpopup="figmpgnTc3pathogenicvariantsdiscussed" rid-ob="figobmpgnTc3pathogenicvariantsdiscussed">Table 4</a>.</p><div id="mpgn.T.c3_pathogenic_variants_discussed" class="table"><h3><span class="label">Table 4. </span></h3><div class="caption"><p><i>C3</i> Pathogenic Variants Discussed in This <i>GeneReview</i></p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1425/table/mpgn.T.c3_pathogenic_variants_discussed/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__mpgn.T.c3_pathogenic_variants_discussed_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_mpgn.T.c3_pathogenic_variants_discussed_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_mpgn.T.c3_pathogenic_variants_discussed_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_mpgn.T.c3_pathogenic_variants_discussed_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Affected Domain</th><th id="hd_h_mpgn.T.c3_pathogenic_variants_discussed_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_mpgn.T.c3_pathogenic_variants_discussed_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.443G&#x0003e;A</td><td headers="hd_h_mpgn.T.c3_pathogenic_variants_discussed_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg148Gln</td><td headers="hd_h_mpgn.T.c3_pathogenic_variants_discussed_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">C3&#x003b2; chain</td><td headers="hd_h_mpgn.T.c3_pathogenic_variants_discussed_1_1_1_4" rowspan="7" colspan="1" style="text-align:left;vertical-align:middle;"><a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_000064.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000064<wbr style="display:inline-block"></wbr>​.3</a><br /><a href="https://www.ncbi.nlm.nih.gov/protein/NP_000055.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_000055<wbr style="display:inline-block"></wbr>​.2</a></td></tr><tr><td headers="hd_h_mpgn.T.c3_pathogenic_variants_discussed_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">c.1855G&#x0003e;A</td><td headers="hd_h_mpgn.T.c3_pathogenic_variants_discussed_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">p.Val619Met</td><td headers="hd_h_mpgn.T.c3_pathogenic_variants_discussed_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Linker</td></tr><tr><td headers="hd_h_mpgn.T.c3_pathogenic_variants_discussed_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">c.3125G&#x0003e;A</td><td headers="hd_h_mpgn.T.c3_pathogenic_variants_discussed_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">p.Arg1042Gln</td><td headers="hd_h_mpgn.T.c3_pathogenic_variants_discussed_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">TED</td></tr><tr><td headers="hd_h_mpgn.T.c3_pathogenic_variants_discussed_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">c.3908G&#x0003e;A</td><td headers="hd_h_mpgn.T.c3_pathogenic_variants_discussed_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">p.Arg1303His</td><td headers="hd_h_mpgn.T.c3_pathogenic_variants_discussed_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">CUBf</td></tr><tr><td headers="hd_h_mpgn.T.c3_pathogenic_variants_discussed_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">c.3959G&#x0003e;A</td><td headers="hd_h_mpgn.T.c3_pathogenic_variants_discussed_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">p.Arg1320Gln</td><td headers="hd_h_mpgn.T.c3_pathogenic_variants_discussed_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">CUBf</td></tr><tr><td headers="hd_h_mpgn.T.c3_pathogenic_variants_discussed_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">c.4552T&#x0003e;C</td><td headers="hd_h_mpgn.T.c3_pathogenic_variants_discussed_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">p.Cys1518Arg</td><td headers="hd_h_mpgn.T.c3_pathogenic_variants_discussed_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">C345C</td></tr><tr><td headers="hd_h_mpgn.T.c3_pathogenic_variants_discussed_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">c.4873T&#x0003e;C</td><td headers="hd_h_mpgn.T.c3_pathogenic_variants_discussed_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">p.Asp1625His</td><td headers="hd_h_mpgn.T.c3_pathogenic_variants_discussed_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">C345C</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin"><i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b>
<i>C3</i> encodes complement component C3, the central activating protein of the AP. This 1,663-amino-acid protein has 15 domains, including the anaphylatoxin (ANA), &#x003b1;NT, CUB (C1r/C1s, Uegf, Bmp1), C345C, thioester (TED), linker (LNK), and anchor domains and eight macroglobulin (MG) domains (see <a class="figpopup" href="/books/NBK1425/figure/mpgn.F5/?report=objectonly" target="object" rid-figpopup="figmpgnF5" rid-ob="figobmpgnF5">Figure 5</a>). C3 is mainly synthesized in the liver, and it is the central protein of the complement system. Spontaneous or proteolytic cleavage of C3 generates the anaphylatoxin C3a (inflammatory effector cells) and the C3b fragment that deposits on cell surfaces triggering the complement cascade activation.</p><div class="iconblock whole_rhythm clearfix ten_col fig" id="figmpgnF5" co-legend-rid="figlgndmpgnF5"><a href="/books/NBK1425/figure/mpgn.F5/?report=objectonly" target="object" title="Figure 5. " class="img_link icnblk_img figpopup" rid-figpopup="figmpgnF5" rid-ob="figobmpgnF5"><img class="small-thumb" src="/books/NBK1425/bin/mpgn-Image005.gif" src-large="/books/NBK1425/bin/mpgn-Image005.jpg" alt="Figure 5. " /></a><div class="icnblk_cntnt" id="figlgndmpgnF5"><h4 id="mpgn.F5"><a href="/books/NBK1425/figure/mpgn.F5/?report=objectonly" target="object" rid-ob="figobmpgnF5">Figure 5. </a></h4><p class="float-caption no_bottom_margin">Schematic representation of complement component C3 The structural organization of C3 contains eight macroglobulins, anaphylatoxin (ANA), &#x003b1;NT, CUB (C1r/C1s, Uegf, Bmp1), C345C, linker, and thioester (TED) domains.</p></div></div><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Most pathogenic variants listed in <a class="figpopup" href="/books/NBK1425/table/mpgn.T.c3_pathogenic_variants_discussed/?report=objectonly" target="object" rid-figpopup="figmpgnTc3pathogenicvariantsdiscussed" rid-ob="figobmpgnTc3pathogenicvariantsdiscussed">Table 4</a> affect proper cleavage of C3 protein by affecting recognition sites for the binding of CFH and CFI, two regulators of complement activation. Pathogenic variants may also produce reduced quantities of C3 protein (i.e., truncating variants or frameshifts that lead to premature stop variants) [<a class="bk_pop" href="#mpgn.REF.mart_nezbarricarte.2010.3702">Mart&#x000ed;nez-Barricarte et al 2010</a>].</p></div><div id="mpgn.CD46"><h4><i>CD46</i></h4><p><b>Gene structure.</b>
<i>CD46</i> (cluster differentiation 46) has 14 exons that encode the 43.7-kd membrane cofactor protein (MCP).</p><p><b>Benign variants.</b> Several variants in <i>CD46</i> have been associated with C3G and define an at-risk haplotype [<a class="bk_pop" href="#mpgn.REF.servais.2007.193">Servais et al 2007</a>, <a class="bk_pop" href="#mpgn.REF.fang.2008.624">Fang et al 2008</a>, <a class="bk_pop" href="#mpgn.REF.servais.2012.454">Servais et al 2012</a>, <a class="bk_pop" href="#mpgn.REF.osborne.2018.2464">Osborne et al 2018</a>].</p><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b>
<i>CD46</i> encodes MCP, a complement regulatory protein of 392 amino acids that is highly expressed in the kidney. It is a transmembrane protein and a member of the regulators of complement activation (RCA), and has eight domains: four short consensus repeat (SCRs 1-4-sushi) domains, which contain ligand-binding domains for decay and cofactor activity; an O-linked-glycosylation site, rich in serine, threonine, and proline (STP) <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a>, which can be alternately spliced; a helical transmembrane domain; and two cytoplasmic topological domains. Its major role in controlling complement activity is to inactivate C3b and C4b by functioning as a cofactor for factor I [<a class="bk_pop" href="#mpgn.REF.servais.2012.454">Servais et al 2012</a>, <a class="bk_pop" href="#mpgn.REF.liszewski.2015.7">Liszewski &#x00026; Atkinson 2015</a>].</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Pathogenic variants in <i>CD46</i> typically lead to reduced surface expression of MCP, which contributes to defective surface regulation of complement [<a class="bk_pop" href="#mpgn.REF.servais.2012.454">Servais et al 2012</a>].</p></div><div id="mpgn.CFB"><h4><i>CFB</i></h4><p><b>Gene structure.</b>
<i>CFB</i> comprises 18 exons that encode complement factor B, which has a molecular weight of 93 kd. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK1425/#mpgn.molgen.TA">Table A</a>.</p><p><b>Benign variants.</b> Benign variants in <i>CFB</i> associated with complement regulation have been described [<a class="bk_pop" href="#mpgn.REF.gold.2006.458">Gold et al 2006</a>].</p><p><b>Pathogenic variants.</b> The p.Ser367Arg <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is in the von Willebrand factor A (VWFa) <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a>, the catalytic unit of Bb, and is a <a class="def" href="/books/n/gene/glossary/def-item/gain-of-function/">gain-of-function</a> variant that contributes to AP dysregulation [<a class="bk_pop" href="#mpgn.REF.imamura.2015.862">Imamura et al 2015</a>].</p><div id="mpgn.T.cfb_pathogenic_variants_discussed" class="table"><h3><span class="label">Table 5. </span></h3><div class="caption"><p><i>CFB</i> Pathogenic Variants Discussed in This <i>GeneReview</i></p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1425/table/mpgn.T.cfb_pathogenic_variants_discussed/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__mpgn.T.cfb_pathogenic_variants_discussed_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_mpgn.T.cfb_pathogenic_variants_discussed_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_mpgn.T.cfb_pathogenic_variants_discussed_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_mpgn.T.cfb_pathogenic_variants_discussed_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_mpgn.T.cfb_pathogenic_variants_discussed_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1099A&#x0003e;C</td><td headers="hd_h_mpgn.T.cfb_pathogenic_variants_discussed_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ser367Arg</td><td headers="hd_h_mpgn.T.cfb_pathogenic_variants_discussed_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_001710.5" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_001710<wbr style="display:inline-block"></wbr>​.5</a><br /><a href="https://www.ncbi.nlm.nih.gov/protein/NP_001701.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_001701<wbr style="display:inline-block"></wbr>​.2</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff has not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin"><i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b>
<i>CFB</i> is composed of 764 amino acids and has five domains: three complement component protein (sushi) domains; a VWFa <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a>; and a peptidase S1 (serine protease) domain. Factor B (fB) is a component of the AP. It binds to C3b and is then cleaved by fD into Ba, a non-catalytic fragment that is released, and Bb, a catalytic subunit that remains bound to C3b to form C3 convertase (C3bBb). The fB cleavage site is near the N-terminus of the VWFa domain.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Pathogenic variants in <i>CFB</i> may lead to <a class="def" href="/books/n/gene/glossary/def-item/gain-of-function/">gain-of-function</a> properties that contribute to the dysregulation of the complement cascade [<a class="bk_pop" href="#mpgn.REF.alberts.2002">Alberts et al 2002</a>, <a class="bk_pop" href="#mpgn.REF.imamura.2015.862">Imamura et al 2015</a>].</p></div><div id="mpgn.CFH"><h4><i>CFH</i></h4><p><b>Gene structure.</b>
<i>CFH</i> has 23 exons that encode complement factor H, a protein of 1,231 amino acids. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK1425/#mpgn.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Benign variants.</b> Several variants of <i>CFH</i> (some of which are common in the population) define an at-risk haplotype that has been associated with C3G [<a class="bk_pop" href="#mpgn.REF.hageman.2005.7227">Hageman et al 2005</a>, <a class="bk_pop" href="#mpgn.REF.servais.2007.193">Servais et al 2007</a>, <a class="bk_pop" href="#mpgn.REF.smith.2007.2447">Smith et al 2007</a>, <a class="bk_pop" href="#mpgn.REF.zhang.2012.265">Zhang et al 2012</a>, <a class="bk_pop" href="#mpgn.REF.johnson.2014.1883">Johnson et al 2014</a>, <a class="bk_pop" href="#mpgn.REF.xiao.2014.465">Xiao et al 2014</a>, <a class="bk_pop" href="#mpgn.REF.merinero.2018.470">Merinero et al 2018</a>, <a class="bk_pop" href="#mpgn.REF.riedl.2017.43">Riedl et al 2017</a>, <a class="bk_pop" href="#mpgn.REF.osborne.2018.2464">Osborne et al 2018</a>].</p><p><b>Pathogenic variants.</b>
<i>CFH</i> pathogenic variants in C3G occur in <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a>, <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a>, and <a class="def" href="/books/n/gene/glossary/def-item/compound-heterozygous/">compound heterozygous</a> states. <i>CFH</i> has been implicated in C3G by the following:</p><ul><li class="half_rhythm"><div>A report of two sisters with DDD who were <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for the <a class="figpopup" href="/books/NBK1425/table/mpgn.T.cfh_pathogenic_variants_discussed/?report=objectonly" target="object" rid-figpopup="figmpgnTcfhpathogenicvariantsdiscussed" rid-ob="figobmpgnTcfhpathogenicvariantsdiscussed">c.670_672delAAG</a> (p.Lys224del) <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>CFH</i> [<a class="bk_pop" href="#mpgn.REF.licht.2006.42">Licht et al 2006</a>, <a class="bk_pop" href="#mpgn.REF.zipfel.2006">Zipfel et al 2006</a>]. Factor H (fH) carrying this pathogenic variant is present in the serum at normal concentrations but is nonfunctional [<a class="bk_pop" href="#mpgn.REF.zipfel.2006">Zipfel et al 2006</a>]. The normal N-terminal activities of fH (C3b binding and complement regulation) are defective, indicating that dysfunctional fH is associated with the development of DDD [<a class="bk_pop" href="#mpgn.REF.licht.2006.42">Licht et al 2006</a>].</div></li><li class="half_rhythm"><div>Studies of skin fibroblasts from a child with fH deficiency and chronic hypocomplementemic renal disease and abnormal fH localization. One copy of a <a class="figpopup" href="/books/NBK1425/table/mpgn.T.cfh_pathogenic_variants_discussed/?report=objectonly" target="object" rid-figpopup="figmpgnTcfhpathogenicvariantsdiscussed" rid-ob="figobmpgnTcfhpathogenicvariantsdiscussed">p.Cys536Arg</a> <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variant and one copy of a <a class="figpopup" href="/books/NBK1425/table/mpgn.T.cfh_pathogenic_variants_discussed/?report=objectonly" target="object" rid-figpopup="figmpgnTcfhpathogenicvariantsdiscussed" rid-ob="figobmpgnTcfhpathogenicvariantsdiscussed">p.Cys959Tyr</a> missense variant were detected in <i>CFH</i>. Both pathogenic variants affect conserved cysteine residues characteristic of the short consensus-repeat (SCR) modules of fH and therefore predict profound changes in the higher-order structure of the 155-kd protein [<a class="bk_pop" href="#mpgn.REF.ault.1997.25168">Ault et al 1997</a>].</div></li><li class="half_rhythm"><div>Two brothers with MPGN were reportedly <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for a <a class="figpopup" href="/books/NBK1425/table/mpgn.T.cfh_pathogenic_variants_discussed/?report=objectonly" target="object" rid-figpopup="figmpgnTcfhpathogenicvariantsdiscussed" rid-ob="figobmpgnTcfhpathogenicvariantsdiscussed">p.Arg127Leu</a> amino acid change in <i>CFH</i> [<a class="bk_pop" href="#mpgn.REF.dragondurey.2004.787">Dragon-Durey et al 2004</a>]. Homozygosity for this <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variant is associated with absence of fH in the serum, suggesting that this variant results in sequestration of the protein in the endoplasmic reticulum.</div></li></ul><div id="mpgn.T.cfh_pathogenic_variants_discussed" class="table"><h3><span class="label">Table 6. </span></h3><div class="caption"><p><i>CFH</i> Pathogenic Variants Discussed in This <i>GeneReview</i></p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1425/table/mpgn.T.cfh_pathogenic_variants_discussed/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__mpgn.T.cfh_pathogenic_variants_discussed_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_mpgn.T.cfh_pathogenic_variants_discussed_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change<br />(Alias&#x000a0;<sup>1</sup>)</th><th id="hd_h_mpgn.T.cfh_pathogenic_variants_discussed_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change<br />(Alias&#x000a0;<sup>1</sup>)</th><th id="hd_h_mpgn.T.cfh_pathogenic_variants_discussed_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_mpgn.T.cfh_pathogenic_variants_discussed_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.380G&#x0003e;T</td><td headers="hd_h_mpgn.T.cfh_pathogenic_variants_discussed_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg127Leu</td><td headers="hd_h_mpgn.T.cfh_pathogenic_variants_discussed_1_1_1_3" rowspan="5" colspan="1" style="text-align:left;vertical-align:middle;"><a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_000186.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000186<wbr style="display:inline-block"></wbr>​.3</a><br /><a href="https://www.ncbi.nlm.nih.gov/protein/NP_000177.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_000177<wbr style="display:inline-block"></wbr>​.2</a></td></tr><tr><td headers="hd_h_mpgn.T.cfh_pathogenic_variants_discussed_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.670_672delAAG</td><td headers="hd_h_mpgn.T.cfh_pathogenic_variants_discussed_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Lys224del<br />(&#x00394;Lys224)</td></tr><tr><td headers="hd_h_mpgn.T.cfh_pathogenic_variants_discussed_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1606T&#x0003e;C<br />(1679T&#x0003e;C)</td><td headers="hd_h_mpgn.T.cfh_pathogenic_variants_discussed_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Cys536Arg<br />(Cys518Arg)</td></tr><tr><td headers="hd_h_mpgn.T.cfh_pathogenic_variants_discussed_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.2655del</td><td headers="hd_h_mpgn.T.cfh_pathogenic_variants_discussed_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg885SerfsTer13</td></tr><tr><td headers="hd_h_mpgn.T.cfh_pathogenic_variants_discussed_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.2876G&#x0003e;A<br />(2949G&#x0003e;A)</td><td headers="hd_h_mpgn.T.cfh_pathogenic_variants_discussed_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Cys959Tyr<br />(Cys991Tyr)</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin"><i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt>1. </dt><dd><div id="mpgn.TF.6.1"><p class="no_margin">Variant designation that does not conform to current naming conventions</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Complement factor H (fH) protein is the key regulator of the alternative pathway of complement and is composed of 1,231 amino acids. Its structural organization is based on 20 homologous repeat domains (short consensus repeats [SCRs] or sushi domains). Each SCR has 60 amino acids. The first four SCRs (1-4) at the N-terminus are essential for fluid-phase complement regulation, binding of fH to C3b, decay acceleration activity of C3bBb, and fI cofactor activity in mediating the cleavage of C3b to iCb3. The last two SCRs (19-20) at the C terminus bind to cell surfaces to regulate C3 convertase in that microenvironment. See <a class="figpopup" href="/books/NBK1425/figure/mpgn.F6/?report=objectonly" target="object" rid-figpopup="figmpgnF6" rid-ob="figobmpgnF6">Figure 6</a>.</p><div class="iconblock whole_rhythm clearfix ten_col fig" id="figmpgnF6" co-legend-rid="figlgndmpgnF6"><a href="/books/NBK1425/figure/mpgn.F6/?report=objectonly" target="object" title="Figure 6. " class="img_link icnblk_img figpopup" rid-figpopup="figmpgnF6" rid-ob="figobmpgnF6"><img class="small-thumb" src="/books/NBK1425/bin/mpgn-Image006.gif" src-large="/books/NBK1425/bin/mpgn-Image006.jpg" alt="Figure 6. " /></a><div class="icnblk_cntnt" id="figlgndmpgnF6"><h4 id="mpgn.F6"><a href="/books/NBK1425/figure/mpgn.F6/?report=objectonly" target="object" rid-ob="figobmpgnF6">Figure 6. </a></h4><p class="float-caption no_bottom_margin">Schematic representation of factor H The 20 bead-like homologous short consensus repeats (SCRs) each have 60 amino acids. The first four SCRs (1-4) (red beads) regulate activation in the fluid phase, binding to C3b, decay acceleration activity, and fI <a href="/books/NBK1425/figure/mpgn.F6/?report=objectonly" target="object" rid-ob="figobmpgnF6">(more...)</a></p></div></div><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b>
<i>CFH</i> pathogenic variants associated with C3G are more frequently found in the N-terminal short consensus repeats (SCRs 1-4), a region essential for fluid-phase complement control. In contrast, in atypical hemolytic uremic syndrome (aHUS), pathogenic variants are more frequently located in the carboxy terminus (SCRs 18-20), a region involved in cell surface regulation.</p></div><div id="mpgn.CFHR1"><h4><i>CFHR1</i></h4><p><b>Gene structure.</b>
<i>CFHR1</i> comprises six exons that encode complement factor H related protein 1. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK1425/#mpgn.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> A <a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a> of exons 2 through 5 results in an abnormal fusion protein (<a class="figpopup" href="/books/NBK1425/figure/mpgn.F3/?report=objectonly" target="object" rid-figpopup="figmpgnF3" rid-ob="figobmpgnF3">Figure 3</a>). The duplication alters the complex oligomerization of the FHR proteins, leading to increased FHR deregulation likely due to increased binding to C3b, iC3b, and C3dg, with decreased fH binding and decreased AP control (see <a class="figpopup" href="/books/NBK1425/figure/mpgn.F3/?report=objectonly" target="object" rid-figpopup="figmpgnF3" rid-ob="figobmpgnF3">Figure 3</a>) [<a class="bk_pop" href="#mpgn.REF.tortajada.2013.2434">Tortajada et al 2013</a>].</p><div id="mpgn.T.cfhr1_pathogenic_variants_discuss" class="table"><h3><span class="label">Table 7. </span></h3><div class="caption"><p><i>CFHR1</i> Pathogenic Variants Discussed in This <i>GeneReview</i></p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1425/table/mpgn.T.cfhr1_pathogenic_variants_discuss/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__mpgn.T.cfhr1_pathogenic_variants_discuss_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_mpgn.T.cfhr1_pathogenic_variants_discuss_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_mpgn.T.cfhr1_pathogenic_variants_discuss_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_mpgn.T.cfhr1_pathogenic_variants_discuss_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_mpgn.T.cfhr1_pathogenic_variants_discuss_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Dup exons 1-4</td><td headers="hd_h_mpgn.T.cfhr1_pathogenic_variants_discuss_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Duplication of all amino acids in SCR 1-4 of protein</td><td headers="hd_h_mpgn.T.cfhr1_pathogenic_variants_discuss_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_002113.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_002113<wbr style="display:inline-block"></wbr>​.2</a><br /><a href="https://www.ncbi.nlm.nih.gov/protein/NP_002104.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_002104<wbr style="display:inline-block"></wbr>​.2</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin"><i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b>
<i>CFHR1</i> encodes complement factor H-related 1 (FHR1), a protein of 330 amino acids and a member of the regulators of complement activation (RCA) family. Its structural organization is highly homologous to fH, although FHR1 has only five SCRs. The last two SCRs (SCRs 4 and 5) share 96%-100% homology to SCRs 19 and 20 of fH. FHR1 homodimerizes through its first two SCRs and also forms heterodimers with FHR2 and FHR5.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Fusion proteins of FHR1 lead to the formation of complex multimers with FHR1, FHR2, and FHR5 that alter complement regulation by outcompeting fH, which results in reduced convertase regulation (see <a class="figpopup" href="/books/NBK1425/figure/mpgn.F3/?report=objectonly" target="object" rid-figpopup="figmpgnF3" rid-ob="figobmpgnF3">Figure 3</a>) [<a class="bk_pop" href="#mpgn.REF.xiao.2016.89">Xiao et al 2016</a>].</p></div><div id="mpgn.CFHR5"><h4><i>CFHR5</i></h4><p><b>Gene structure.</b>
<i>CFHR5</i> has ten exons that encode complement factor H-related 5 (FHR5), a protein of 551 amino acids organized into nine SCRs. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK1425/#mpgn.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Benign variants.</b> Several <i>CFHR5</i> variants (some of which are common in the population) are associated with C3G and define an at-risk haplotype [<a class="bk_pop" href="#mpgn.REF.abreraabeleda.2006.582">Abrera-Abeleda et al 2006</a>, <a class="bk_pop" href="#mpgn.REF.zipfel.2015.21">Zipfel et al 2015</a>, <a class="bk_pop" href="#mpgn.REF.osborne.2018.2464">Osborne et al 2018</a>].</p><p><b>Pathogenic variants.</b> Pathogenic variants are more frequently associated with C3GN than with DDD (CFHR5 nephropathy is a type of C3GN) [<a class="bk_pop" href="#mpgn.REF.goicoechea_de_jorge.2009.2822">Goicoechea de Jorge et al 2009</a>].</p><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The normal gene product encoded by <i>CFHR5</i> is complement factor H-related protein 5 (FHR5), a plasma protein organized like fH in repetitive SCRs. FHR5 has nine SCRs and possesses fI-dependent cofactor activity that leads to inactivation of C3b [<a class="bk_pop" href="#mpgn.REF.mcrae.2001.6747">McRae et al 2001</a>, <a class="bk_pop" href="#mpgn.REF.rodr_guez_de_c_rdoba.2004.355">Rodr&#x000ed;guez de C&#x000f3;rdoba et al 2004</a>, <a class="bk_pop" href="#mpgn.REF.mcrae.2005.6250">McRae et al 2005</a>]. In 92 renal biopsies from patients with different glomerular diseases, FHR5 was present in all complement-containing glomerular immune deposits [<a class="bk_pop" href="#mpgn.REF.murphy.2002.24">Murphy et al 2002</a>], suggesting that FHR5 plays an important role in protecting the glomerulus from complement activation. The precise role of FHR5 in the physiopathology of C3G remains to be determined.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Several abnormal gene products of <i>CFHR5</i> have been reported in association with C3G. These products usually arise as a consequence of <a class="def" href="/books/n/gene/glossary/def-item/nonallelic-homologous-recombination/">nonallelic homologous recombination</a>, which results in hybrid gene formation (see <a class="figpopup" href="/books/NBK1425/figure/mpgn.F3/?report=objectonly" target="object" rid-figpopup="figmpgnF3" rid-ob="figobmpgnF3">Figure 3</a>).</p><p>The presence of <i>CFHR5</i> pathogenic variants in C3G is consistent with the hypothesis that FHRs play an important role in the complement regulation and disease pathogenesis [<a class="bk_pop" href="#mpgn.REF.abreraabeleda.2006.582">Abrera-Abeleda et al 2006</a>, <a class="bk_pop" href="#mpgn.REF.zhang.2013.1820">Zhang et al 2013</a>].</p></div><div id="mpgn.CFI"><h4><i>CFI</i></h4><p><b>Gene structure.</b>
<i>CFI</i> comprises 13 exons that encode complement factor I (fI), which has a molecular weight of 33 kd. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK1425/#mpgn.molgen.TA">Table A</a>.</p><p><b>Benign variants.</b> Several <i>CFI</i> variants (some of which are common in the population) are associated with C3G and define an at-risk haplotype [<a class="bk_pop" href="#mpgn.REF.fremeauxbacchi.2013.554">Fremeaux-Bacchi et al 2013</a>, <a class="bk_pop" href="#mpgn.REF.imamura.2015.862">Imamura et al 2015</a>, <a class="bk_pop" href="#mpgn.REF.chauvet.2017.1437">Chauvet et al 2017</a>, <a class="bk_pop" href="#mpgn.REF.osborne.2018.2464">Osborne et al 2018</a>].</p><p><b>Pathogenic variants</b></p><ul><li class="half_rhythm"><div>c-4C&#x0003e;T &#x02013; in the Kozac sequence. This noncoding variant is associated with DDD [<a class="bk_pop" href="#mpgn.REF.iatropoulos.2016.131">Iatropoulos et al 2016</a>].</div></li><li class="half_rhythm"><div>p.Gly57Asp &#x02013; in FIMAC <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a>, a region for fI-C3b degradation [<a class="bk_pop" href="#mpgn.REF.iatropoulos.2016.131">Iatropoulos et al 2016</a>]</div></li><li class="half_rhythm"><div>c.Ala240Gly &#x02013; in LDL receptor class A 1 and associated with C3G, aHUS, and AMD. The variant results in partial reduction in secretion [<a class="bk_pop" href="#mpgn.REF.nilsson.2010.172">Nilsson et al 2010</a>].</div></li></ul><div id="mpgn.T.cfi_pathogenic_variants_discussed" class="table"><h3><span class="label">Table 8. </span></h3><div class="caption"><p><i>CFI</i> Pathogenic Variants Discussed in This <i>GeneReview</i></p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1425/table/mpgn.T.cfi_pathogenic_variants_discussed/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__mpgn.T.cfi_pathogenic_variants_discussed_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_mpgn.T.cfi_pathogenic_variants_discussed_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_mpgn.T.cfi_pathogenic_variants_discussed_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change<br />(Alias&#x000a0;<sup>1</sup>)</th><th id="hd_h_mpgn.T.cfi_pathogenic_variants_discussed_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_mpgn.T.cfi_pathogenic_variants_discussed_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.719C&#x0003e;G</td><td headers="hd_h_mpgn.T.cfi_pathogenic_variants_discussed_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ala240Gly<br />(Ala222Gly)</td><td headers="hd_h_mpgn.T.cfi_pathogenic_variants_discussed_1_1_1_3" rowspan="3" colspan="1" style="text-align:left;vertical-align:middle;"><a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_000204.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000204<wbr style="display:inline-block"></wbr>​.3</a><br /><a href="https://www.ncbi.nlm.nih.gov/protein/NP_000195.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_000195<wbr style="display:inline-block"></wbr>​.2</a></td></tr><tr><td headers="hd_h_mpgn.T.cfi_pathogenic_variants_discussed_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.-4C&#x0003e;T</td><td headers="hd_h_mpgn.T.cfi_pathogenic_variants_discussed_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_mpgn.T.cfi_pathogenic_variants_discussed_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.170G&#x0003e;A</td><td headers="hd_h_mpgn.T.cfi_pathogenic_variants_discussed_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gly57Asp</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin"><i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt>1. </dt><dd><div id="mpgn.TF.8.1"><p class="no_margin">Variant designation that does not conform to current naming conventions</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b>
<i>CFI</i> encodes complement fI, a protein of 583 amino acids synthesized in the liver. The fI protein cleaves fluid-phase and cell-bound C3b and C4b, inhibiting their activity in the complement cascade. Factor H and several other RCA proteins are obligatory cofactors for fI activity.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Abnormal fI may lead to a partial reduction in secreted fI, thus compromising its cofactor activity with fH [<a class="bk_pop" href="#mpgn.REF.servais.2012.454">Servais et al 2012</a>]. Deficiency in fI can lead to complement dysregulation and consequently low serum levels of other complement proteins.</p></div><div id="mpgn.DGKE"><h4><i>DGKE</i></h4><p><b>Gene structure.</b>
<i>DGKE</i> comprises 11 exons that encode diacylglycerol kinase epsilon, which has a molecular weight of 64 kd. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK1425/#mpgn.molgen.TA">Table A</a>.</p><p><b>Benign variants.</b> Several <i>DGKE</i> variants (some of which are common in the population) are associated with C3G and define an at-risk haplotype [<a class="bk_pop" href="#mpgn.REF.osborne.2018.2464">Osborne et al 2018</a>].</p><p><b>Pathogenic variants.</b> Several <a class="def" href="/books/n/gene/glossary/def-item/loss-of-function/">loss-of-function</a> variants have been associated with C3G including the following:</p><ul><li class="half_rhythm"><div>p.Gln43Ter [<a class="bk_pop" href="#mpgn.REF.ozaltin.2013.377">Ozaltin et al 2013</a>]</div></li><li class="half_rhythm"><div>p.Lys101Ter [<a class="bk_pop" href="#mpgn.REF.westland.2014.1408">Westland et al 2014</a>]</div></li><li class="half_rhythm"><div>c.610delA [<a class="bk_pop" href="#mpgn.REF.ozaltin.2013.377">Ozaltin et al 2013</a>]</div></li><li class="half_rhythm"><div>p.Trp322Ter [<a class="bk_pop" href="#mpgn.REF.azukaitis.2017.3066">Azukaitis et al 2017</a>]</div></li><li class="half_rhythm"><div>p.Trp350Ter [<a class="bk_pop" href="#mpgn.REF.ozaltin.2013.377">Ozaltin et al 2013</a>]</div></li></ul><div id="mpgn.T.dgke_pathogenic_variants_discusse" class="table"><h3><span class="label">Table 9. </span></h3><div class="caption"><p><i>DGKE</i> Pathogenic Variants Discussed in This <i>GeneReview</i></p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1425/table/mpgn.T.dgke_pathogenic_variants_discusse/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__mpgn.T.dgke_pathogenic_variants_discusse_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_mpgn.T.dgke_pathogenic_variants_discusse_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_mpgn.T.dgke_pathogenic_variants_discusse_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_mpgn.T.dgke_pathogenic_variants_discusse_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_mpgn.T.dgke_pathogenic_variants_discusse_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.127C&#x0003e;T</td><td headers="hd_h_mpgn.T.dgke_pathogenic_variants_discusse_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gln43Ter</td><td headers="hd_h_mpgn.T.dgke_pathogenic_variants_discusse_1_1_1_3" rowspan="5" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/entrez/viewer.fcgi?val=NM_003647.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_003647<wbr style="display:inline-block"></wbr>​.2</a><br /><a href="https://www.ncbi.nlm.nih.gov/protein/NP_003638.1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_003638<wbr style="display:inline-block"></wbr>​.1</a></td></tr><tr><td headers="hd_h_mpgn.T.dgke_pathogenic_variants_discusse_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.301A&#x0003e;T</td><td headers="hd_h_mpgn.T.dgke_pathogenic_variants_discusse_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Lys101Ter</td></tr><tr><td headers="hd_h_mpgn.T.dgke_pathogenic_variants_discusse_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.610delA</td><td headers="hd_h_mpgn.T.dgke_pathogenic_variants_discusse_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Thr204GlnfsTer6</td></tr><tr><td headers="hd_h_mpgn.T.dgke_pathogenic_variants_discusse_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.966G&#x0003e;A</td><td headers="hd_h_mpgn.T.dgke_pathogenic_variants_discusse_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Trp322Ter</td></tr><tr><td headers="hd_h_mpgn.T.dgke_pathogenic_variants_discusse_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1050G&#x0003e;A</td><td headers="hd_h_mpgn.T.dgke_pathogenic_variants_discusse_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Trp350Ter</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Note on variant classification: Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin">Note on nomenclature: <i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b>
<i>DGKE</i> is unrelated to the complement pathway. <i>DGKE</i> encodes diacylglycerol kinase epsilon (DGKE), a lipid kinase of 567 amino acids expressed in podocytes, glomerular capillary endothelial cells, and platelets. DGKE plays a key role in signal transduction by affecting the balance between diacylglycerol kinase and phosphatidic acid, thus controlling DAG levels within the cell [<a class="bk_pop" href="#mpgn.REF.lemaire.2013.531">Lemaire et al 2013</a>]. The role of DGKE in complement activation is minimal; however, it is believed to play an essential role in normal podocyte function [<a class="bk_pop" href="#mpgn.REF.ozaltin.2013.377">Ozaltin et al 2013</a>].</p><p>In the kidney, DGKE is ubiquitously expressed in podocytes and endothelial cells. Although <i>Dgke</i>
null mice do not have spontaneous clinical signs of kidney disease and have normal serum creatinine and urinary albumin, they develop subclinical microscopic anomalies of the glomerular endothelium that worsen with age, as well as glomerular capillary occlusion when exposed to nephrotoxic serum [<a class="bk_pop" href="#mpgn.REF.zhu.2016.f895">Zhu et al 2016</a>].</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Abnormal DGKE may lead to prothrombosis through sustained signaling by arachidonic acid-containing diacylglycerol (AA-DAG) [<a class="bk_pop" href="#mpgn.REF.lemaire.2013.531">Lemaire et al 2013</a>].</p></div></div></div><div id="mpgn.References"><h2 id="_mpgn_References_">References</h2><div id="mpgn.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.abreraabeleda.2011.1551">Abrera-Abeleda MA, Nishimura C, Frees K, Jones M, Maga T, Katz LM, Zhang Y, Smith RJH. Allele variants of complement genes associated with dense deposit disease. <span><span class="ref-journal">J Am Soc Nephrol. </span>2011;<span class="ref-vol">22</span>:1551–9.</span> [<a href="/pmc/articles/PMC3148710/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3148710</span></a>] [<a href="/pubmed/21784901" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21784901</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.abreraabeleda.2006.582">Abrera-Abeleda MA, Nishimura C, Smith JL, Sethi S, McRae JL, Murphy BF, Silvestri G, Skerka C, J&#x000f3;zsi M, Zipfel PF, Hageman GS, Smith RJ. Variations in the complement regulatory genes factor H (CFH) and factor H related 5 (CFHR5) are associated with membranoproliferative glomerulonephritis type II (dense deposit disease). <span><span class="ref-journal">J Med Genet. </span>2006;<span class="ref-vol">43</span>:582–9.</span> [<a href="/pmc/articles/PMC2564553/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2564553</span></a>] [<a href="/pubmed/16299065" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16299065</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.alberts.2002">Alberts B, Johnson A, Lewis J, et al. Studying gene expression and function. In: <em>Molecular Biology of the Cell</em>. 4 ed. New York: Garland Science. Available <a href="https://www.ncbi.nlm.nih.gov/books/NBK26818/" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2002. Accessed 11-22-19.</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.angelo.2011.291">Angelo JR, Bell CS, Braun MC. Allograft failure in kidney transplant recipients with membranoproliferative glomerulonephritis. <span><span class="ref-journal">Am J Kidney Dis. </span>2011;<span class="ref-vol">57</span>:291–9.</span> [<a href="/pubmed/21215503" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21215503</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.appel.2005.1392">Appel GB, Cook HT, Hageman G, Jennette JC, Kashgarian M, Kirschfink M, Lambris JD, Lanning L, Lutz HU, Meri S, Rose NR, Salant DJ, Sethi S, Smith RJ, Smoyer W, Tully HF, Tully SP, Walker P, Welsh M, Wurzner R, Zipfel PF. Membranoproliferative glomerulonephritis type II (dense deposit disease): an update. <span><span class="ref-journal">J Am Soc Nephrol. </span>2005;<span class="ref-vol">16</span>:1392–403.</span> [<a href="/pubmed/15800116" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15800116</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.athanasiou.2011.1436">Athanasiou Y, Voskarides K, Gale DP, Damianou L, Patsias C, Zavros M, Maxwell PH, Cook HT, Demosthenous P, Hadjisavvas A, Kyriacou K, Zouvani I, Pierides A, Deltas C. Familial C3 glomerulopathy associated with CFHR5 mutations: clinical characteristics of 91 patients in 16 pedigrees. <span><span class="ref-journal">Clin J Am Soc Nephrol. </span>2011;<span class="ref-vol">6</span>:1436–46.</span> [<a href="/pmc/articles/PMC3109942/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3109942</span></a>] [<a href="/pubmed/21566112" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21566112</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.ault.1997.25168">Ault BH, Schmidt BZ, Fowler NL, Kashtan CE, Ahmed AE, Vogt BA, Colten HR. Human factor H deficiency. Mutations in framework cysteine residues and block in H protein secretion and intracellular catabolism. <span><span class="ref-journal">J Biol Chem. </span>1997;<span class="ref-vol">272</span>:25168–75.</span> [<a href="/pubmed/9312129" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9312129</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.azukaitis.2017.3066">Azukaitis K, Simkova E, Majid MA, Galiano M, Benz K, Amann K, Bockmeyer C, Gajjar R, Meyers KE, Cheong HI, Lange-Sperandio B, Jungraithmayr T, Fremeaux-Bacchi V, Bergmann C, Bereczki C, Miklaszewska M, Csuka D, Proh&#x000e1;szka Z, Gipson P, Sampson MG, Lemaire M, Schaefer F. The phenotypic spectrum of nephropathies associated with mutations in diacylglycerol kinase &#x003b5;. <span><span class="ref-journal">J Am Soc Nephrol. </span>2017;<span class="ref-vol">28</span>:3066–75.</span> [<a href="/pmc/articles/PMC5619969/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5619969</span></a>] [<a href="/pubmed/28526779" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28526779</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.barbour.2013a.1685">Barbour TD, Pickering MC, Cook HT. Recent insights into C3 glomerulopathy. <span><span class="ref-journal">Nephrol Dial Transplant. </span>2013a;<span class="ref-vol">28</span>:1685–93.</span> [<a href="/pmc/articles/PMC3707523/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3707523</span></a>] [<a href="/pubmed/23479095" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23479095</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.barbour.2013b.493">Barbour TD, Pickering MC, Terence Cook H. Dense deposit disease and C3 glomerulopathy. <span><span class="ref-journal">Semin Nephrol. </span>2013b;<span class="ref-vol">33</span>:493–507.</span> [<a href="/pmc/articles/PMC3820036/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3820036</span></a>] [<a href="/pubmed/24161036" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24161036</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.besbas.2014.457">Besbas N, Gulhan B, Gucer S, Korkmaz E, Ozaltin F. A novel CFHR5 mutation associated with C3 glomerulonephritis in a Turkish girl. <span><span class="ref-journal">J Nephrol. </span>2014;<span class="ref-vol">27</span>:457–60.</span> [<a href="/pubmed/24536001" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24536001</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.blanc.2015.5129">Blanc C, Togarsimalemath SK, Chauvet S, Le Quintrec M, Moulin B, Buchler M, Jokiranta TS, Roumenina LT, Fremeaux-Bacchi V, Dragon-Durey MA. Anti-factor H autoantibodies in C3 glomerulopathies and in atypical hemolytic uremic syndrome: one target, two diseases. <span><span class="ref-journal">J Immunol. </span>2015;<span class="ref-vol">194</span>:5129–38.</span> [<a href="/pubmed/25917093" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25917093</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.bomback.2012.748">Bomback AS, Smith RJ, Barile GR, Zhang Y, Heher EC, Herlitz L, Stokes MB, Markowitz GS, D'Agati VD, Canetta PA, Radhakrishnan J, Appel GB. Eculizumab for dense deposit disease and C3 glomerulonephritis. <span><span class="ref-journal">Clin J Am Soc Nephrol. </span>2012;<span class="ref-vol">7</span>:748–56.</span> [<a href="/pmc/articles/PMC3338285/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3338285</span></a>] [<a href="/pubmed/22403278" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22403278</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.bu.2016.1245">Bu F, Borsa NG, Jones MB, Takanami E, Nishimura C, Hauer JJ, Azaiez H, Black-Ziegelbein EA, Meyer NC, Kolbe DL, Li Y, Frees K, Schnieders MJ, Thomas C, Nester C, Smith RJ. High-throughput genetic testing for thrombotic microangiopathies and C3 glomerulopathies. <span><span class="ref-journal">J Am Soc Nephrol. </span>2016;<span class="ref-vol">27</span>:1245–53.</span> [<a href="/pmc/articles/PMC4814193/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4814193</span></a>] [<a href="/pubmed/26283675" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26283675</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.cameron.1983.175">Cameron JS, Turner DR, Heaton J, Williams DG, Ogg CS, Chantler C, Haycock GB, Hicks J. Idiopathic mesangiocapillary glomerulonephritis. Comparison of types I and II in children and adults and long-term prognosis. <span><span class="ref-journal">Am J Med. </span>1983;<span class="ref-vol">74</span>:175–92.</span> [<a href="/pubmed/6337487" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6337487</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.cebeci.2016.260">Cebeci Z, Bayraktar S, Oray M, Kir N. Multimodal imaging of membranoproliferative glomerulonephritis type II. <span><span class="ref-journal">Saudi J Ophthalmol. </span>2016;<span class="ref-vol">30</span>:260–3.</span> [<a href="/pmc/articles/PMC5161817/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5161817</span></a>] [<a href="/pubmed/28003788" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28003788</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.chauvet.2017.1437">Chauvet S, Fremeaux-Bacchi V, Petitprez F, Karras A, Daniel L, Burtey S, Choukroun G, Delmas Y, Guerrot D, Fran&#x000e7;ois A, Le Quintrec M, Javaugue V, Ribes D, Vrigneaud L, Arnulf B, Goujon JM, Ronco P, Touchard G, Bridoux F. Treatment of B-cell disorder improves renal outcome of patients with monoclonal gammopathy-associated C3 glomerulopathy. <span><span class="ref-journal">Blood. </span>2017;<span class="ref-vol">129</span>:1437–47.</span> [<a href="/pubmed/28069603" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28069603</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.chen.2011.2340">Chen Q, Muller D, Rudolph B, Hartmann A, Kuwertz-Broking E, Wu K, Kirschfink M, Skerka C, Zipfel PF. Combined C3b and factor B autoantibodies and MPGN type II. <span><span class="ref-journal">N Engl J Med. </span>2011;<span class="ref-vol">365</span>:2340–2.</span> [<a href="/pubmed/22168663" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22168663</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.chen.2014.145">Chen Q, Wiesener M, Eberhardt HU, Hartmann A, Uzonyi B, Kirschfink M, Amann K, Buettner M, Goodship T, Hugo C, Skerka C, Zipfel PF. Complement factor H-related hybrid protein deregulates complement in dense deposit disease. <span><span class="ref-journal">J Clin Invest. </span>2014;<span class="ref-vol">124</span>:145–55.</span> [<a href="/pmc/articles/PMC3871254/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3871254</span></a>] [<a href="/pubmed/24334459" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24334459</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.cook.2017.248">Cook HT. C3 glomerulopathy. <span><span class="ref-journal">F1000Res. </span>2017;<span class="ref-vol">6</span>:248.</span> [<a href="/pmc/articles/PMC5357035/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5357035</span></a>] [<a href="/pubmed/28357053" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28357053</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.dagati.2012.379">D'Agati VD, Bomback AS. C3 glomerulopathy: what's in a name? <span><span class="ref-journal">Kidney Int. </span>2012;<span class="ref-vol">82</span>:379–81.</span> [<a href="/pubmed/22846813" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22846813</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.daina.2012.1161">Daina E, Noris M, Remuzzi G. Eculizumab in a patient with dense-deposit disease. <span><span class="ref-journal">N Engl J Med. </span>2012;<span class="ref-vol">366</span>:1161–3.</span> [<a href="/pubmed/22435382" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22435382</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.dalvin.2016.72">Dalvin LA, Fervenza FC, Sethi S, Pulido JS. Shedding light on fundus drusen associated with membranoproliferative glomerulonephritis: breaking stereotypes of types I, II, and III. <span><span class="ref-journal">Retin Cases Brief Rep. </span>2016;<span class="ref-vol">10</span>:72–8.</span> [<a href="/pubmed/26110522" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26110522</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.deltas.2013.189">Deltas C, Gale D, Cook T, Voskarides K, Athanasiou Y, Pierides A. C3 glomerulonephritis/CFHR5 nephropathy is an endemic disease in Cyprus: clinical and molecular findings in 21 families. <span><span class="ref-journal">Adv Exp Med Biol. </span>2013;<span class="ref-vol">735</span>:189–96.</span> [<a href="/pubmed/23402027" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23402027</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.dragondurey.2004.787">Dragon-Durey MA, Fremeaux-Bacchi V, Loirat C, Blouin J, Niaudet P, Deschenes G, Coppo P, Herman Fridman W, Weiss L. Heterozygous and homozygous factor h deficiencies associated with hemolytic uremic syndrome or membranoproliferative glomerulonephritis: report and genetic analysis of 16 cases. <span><span class="ref-journal">J Am Soc Nephrol. </span>2004;<span class="ref-vol">15</span>:787–95.</span> [<a href="/pubmed/14978182" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14978182</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.dsouza.2009.824">D'Souza YB, Jones CJ, Short CD, Roberts IS, Bonshek RE. Oligosaccharide composition is similar in drusen and dense deposits in membranoproliferative glomerulonephritis type II. <span><span class="ref-journal">Kidney Int. </span>2009;<span class="ref-vol">75</span>:824–7.</span> [<a href="/pubmed/19177159" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19177159</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.eisinger.1972.343">Eisinger AJ, Shortland JR, Moorhead PJ. Renal disease in partial lipodystrophy. <span><span class="ref-journal">Q J Med. </span>1972;<span class="ref-vol">41</span>:343–54.</span> [<a href="/pubmed/4561162" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 4561162</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.fang.2008.624">Fang CJ, Fremeaux-Bacchi V, Liszewski MK, Pianetti G, Noris M, Goodship TH, Atkinson JP. Membrane cofactor protein mutations in atypical hemolytic uremic syndrome (aHUS), fatal Stx-HUS, C3 glomerulonephritis, and the HELLP syndrome. <span><span class="ref-journal">Blood. </span>2008;<span class="ref-vol">111</span>:624–32.</span> [<a href="/pmc/articles/PMC2200836/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2200836</span></a>] [<a href="/pubmed/17914026" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17914026</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.fremeauxbacchi.2013.554">Fremeaux-Bacchi V, Fakhouri F, Garnier A, Bienaim&#x000e9; F, Dragon-Durey MA, Ngo S, Moulin B, Servais A, Provot F, Rostaing L, Burtey S, Niaudet P, Desch&#x000ea;nes G, Lebranchu Y, Zuber J, Loirat C. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. <span><span class="ref-journal">Clin J Am Soc Nephrol. </span>2013;<span class="ref-vol">8</span>:554–62.</span> [<a href="/pmc/articles/PMC3613948/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3613948</span></a>] [<a href="/pubmed/23307876" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23307876</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.fremeauxbacchi.2008.2093">Fremeaux-Bacchi V, Fakhouri F, Loirat C. Hemolytic-uremic syndrome: what is the mechanism? <span><span class="ref-journal">Rev Prat. </span>2008;<span class="ref-vol">58</span>:2093–6.</span> [<a href="/pubmed/19213534" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19213534</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.fremeauxbacchi.1994.811">Fremeaux-Bacchi V, Weiss L, Brun P, Kazatchkine MD. Selective disappearance of C3NeF IgG autoantibody in the plasma of a patient with membranoproliferative glomerulonephritis following renal transplantation. <span><span class="ref-journal">Nephrol Dial Transplant. </span>1994;<span class="ref-vol">9</span>:811–4.</span> [<a href="/pubmed/7970124" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7970124</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.fujita.2007.1957">Fujita T, Nozu K, Iijima K, Kamioka I, Kaito H, Tanaka R, Nakanishi K, Matsuo M, Yoshikawa N. Long-term follow-up of juvenile acute nonproliferative glomerulitis (JANG). <span><span class="ref-journal">Pediatr Nephrol. </span>2007;<span class="ref-vol">22</span>:1957–61.</span> [<a href="/pubmed/17674054" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17674054</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.gale.2010.794">Gale DP, de Jorge EG, Cook HT, Mart&#x000ed;nez-Barricarte R, Hadjisavvas A, McLean AG, Pusey CD, Pierides A, Kyriacou K, Athanasiou Y, Voskarides K, Deltas C, Palmer A, Fremeaux-Bacchi V, de Cordoba SR, Maxwell PH, Pickering MC. Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis. <span><span class="ref-journal">Lancet. </span>2010;<span class="ref-vol">376</span>:794–801.</span> [<a href="/pmc/articles/PMC2935536/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2935536</span></a>] [<a href="/pubmed/20800271" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20800271</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.gale.2014">Gale DP, Owen-Casey M. Membranoproliferative glomerulonephritis and C3 glomerulopathy. In: Harber M, ed. <em>Practical Nephrology</em>. London: Springer; 2014:189-202.</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.goicoechea_de_jorge.2009.2822">Goicoechea de Jorge E, Gale DP, Cook HT, Mart&#x000ed;nez-Barricate A, Hadjisavvas A, Pusey CD, Palmer A, Fremeaux-Bacchi V, Rodriguez de Cordoba S, Maxwell PH, Pickering MC. A mutant complement factor H-related 5 protein is associated with familial C3 glomerulonephritis. <span><span class="ref-journal">Mol Immunol. </span>2009;<span class="ref-vol">46</span>:2822.</span></div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.gold.2006.458">Gold B, Merriam JE, Zernant J, Hancox LS, Taiber AJ, Gehrs K, Cramer K, Neel J, Bergeron J, Barile GR, Smith RT, Hageman GS, Dean M, Allikmets R, et al.  Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration. <span><span class="ref-journal">Nat Genet. </span>2006;<span class="ref-vol">38</span>:458–62.</span> [<a href="/pmc/articles/PMC2921703/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2921703</span></a>] [<a href="/pubmed/16518403" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16518403</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.goodship.2017.539">Goodship TH, Cook HT, Fakhouri F, Fervenza FC, Fremeaux-Bacchi V, Kavanagh D, Nester CM, Noris M, Pickering MC, Rodr&#x000ed;guez de C&#x000f3;rdoba S, Roumenina LT, Sethi S, Smith RJ. Conference Participants. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. <span><span class="ref-journal">Kidney Int. </span>2017;<span class="ref-vol">91</span>:539–51.</span> [<a href="/pubmed/27989322" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27989322</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.habib.1975.204">Habib R, Gubler MC, Loirat C, Maiz HB, Levy M. Dense deposit disease: a variant of membranoproliferative glomerulonephritis. <span><span class="ref-journal">Kidney Int. </span>1975;<span class="ref-vol">7</span>:204–15.</span> [<a href="/pubmed/1095806" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1095806</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.hageman.2005.7227">Hageman GS, Anderson DH, Johnson LV, Hancox LS, Taiber AJ, Hardisty LI, Hageman JL, Stockman HA, Borchardt JD, Gehrs KM, Smith RJ, Silvestri G, Russell SR, Klaver CC, Barbazetto I, Chang S, Yannuzzi LA, Barile GR, Merriam JC, Smith RT, Olsh AK, Bergeron J, Zernant J, Merriam JE, Gold B, Dean M, Allikmets R. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. <span><span class="ref-journal">Proc Natl Acad Sci U S A. </span>2005;<span class="ref-vol">102</span>:7227–32.</span> [<a href="/pmc/articles/PMC1088171/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1088171</span></a>] [<a href="/pubmed/15870199" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15870199</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.hulleman.2016.153">Hulleman JD. Malattia Leventinese/Doyne honeycomb retinal dystrophy: similarities to age-related macular degeneration and potential therapies. <span><span class="ref-journal">Adv Exp Med Biol. </span>2016;<span class="ref-vol">854</span>:153–8.</span> [<a href="/pubmed/26427406" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26427406</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.iatropoulos.2016.131">Iatropoulos P, Noris M, Mele C, Piras R, Valoti E, Bresin E, Curreri M, Mondo E, Zito A, Gamba S, Bettoni S, Murer L, Fremeaux-Bacchi V, Vivarelli M, Emma F, Daina E, Remuzzi G. Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome. <span><span class="ref-journal">Mol Immunol. </span>2016;<span class="ref-vol">71</span>:131–42.</span> [<a href="/pubmed/26895476" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26895476</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.imamura.2015.862">Imamura H, Konomoto T, Tanaka E, Hisano S, Yoshida Y, Fujimura Y, Miyata T, Nunoi H. Familial C3 glomerulonephritis associated with mutations in the gene for complement factor B. <span><span class="ref-journal">Nephrol Dial Transplant. </span>2015;<span class="ref-vol">30</span>:862–4.</span> [<a href="/pubmed/25758434" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25758434</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.johnson.2014.1883">Johnson SA, Wong EK, Taylor CM. Making sense of the spectrum of glomerular disease associated with complement dysregulation. <span><span class="ref-journal">Pediatr Nephrol. </span>2014;<span class="ref-vol">29</span>:1883–94.</span> [<a href="/pubmed/23852337" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23852337</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.kambham.2012.338">Kambham N. Postinfectious glomerulonephritis. <span><span class="ref-journal">Adv Anat Pathol. </span>2012;<span class="ref-vol">19</span>:338–47.</span> [<a href="/pubmed/22885383" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22885383</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.khalighi.2016.397">Khalighi MA, Wang S, Henriksen KJ, Bock M, Keswani M, Meehan SM, Chang A. Revisiting post-infectious glomerulonephritis in the emerging era of C3 glomerulopathy. <span><span class="ref-journal">Clin Kidney J. </span>2016;<span class="ref-vol">9</span>:397–402.</span> [<a href="/pmc/articles/PMC4886922/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4886922</span></a>] [<a href="/pubmed/27274823" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27274823</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.kobayashi.2017.13">Kobayashi Y, Yang S, Nykamp K, Garcia J, Lincoln SE, Topper SE. Pathogenic variant burden in the ExAC database: an empirical approach to evaluating population data for clinical variant interpretation. <span><span class="ref-journal">Genome Med. </span>2017;<span class="ref-vol">9</span>:13.</span> [<a href="/pmc/articles/PMC5295186/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5295186</span></a>] [<a href="/pubmed/28166811" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28166811</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.kurtz.2002.135">Kurtz KA, Schlueter AJ. Management of membranoproliferative glomerulonephritis type II with plasmapheresis. <span><span class="ref-journal">J Clin Apher. </span>2002;<span class="ref-vol">17</span>:135–7.</span> [<a href="/pubmed/12378549" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12378549</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.lemaire.2013.531">Lemaire M, Fremeaux-Bacchi V, Schaefer F, Choi M, Tang WH, Le Quintrec M, Fakhouri F, Taque S, Nobili F, Mart&#x000ed;nez F, Ji W, Overton JD, Mane SM, N&#x000fc;rnberg G, Altm&#x000fc;ller J, Thiele H, Morin D, Deschenes G, Baudouin V, Llanas B, Collard L, Majid MA, Simkova E, N&#x000fc;rnberg P, Rioux-Leclerc N, Moeckel GW, Gubler MC, Hwa J, Loirat C, Lifton RP. Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. <span><span class="ref-journal">Nat Genet. </span>2013;<span class="ref-vol">45</span>:531–6.</span> [<a href="/pmc/articles/PMC3719402/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3719402</span></a>] [<a href="/pubmed/23542698" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23542698</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.licht.2009.271">Licht C, Fremeaux-Bacchi V. Hereditary and acquired complement dysregulation in membranoproliferative glomerulonephritis. <span><span class="ref-journal">Thromb Haemost. </span>2009;<span class="ref-vol">101</span>:271–8.</span> [<a href="/pubmed/19190809" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19190809</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.licht.2006.42">Licht C, Heinen S, Jozsi M, Loschmann I, Saunders RE, Perkins SJ, Skerka C, Kirschfink M, Hoppe B, Zipfel PF. Deletion of Lys224 in regulatory domain 4 of factor H reveals a novel pathomechanism for dense deposit disease (MPGNII). <span><span class="ref-journal">Kidney Int. </span>2006;<span class="ref-vol">70</span>:42–50.</span> [<a href="/pubmed/16612335" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16612335</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.licht.2008">Licht C, Mengel M. Membranoproliferative glomerulonephritis. In: Geary DF, Schaefer F, eds. <em>Comprehensive Pediatric Nephrology</em>. 1 ed. Philadelphia, PA: Mosby; 2008:269-89.</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.liszewski.2015.7">Liszewski MK, Atkinson JP. Complement regulator CD46: genetic variants and disease associations. <span><span class="ref-journal">Hum Genomics. </span>2015;<span class="ref-vol">9</span>:7.</span> [<a href="/pmc/articles/PMC4469999/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4469999</span></a>] [<a href="/pubmed/26054645" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26054645</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.lu.2007.295">Lu DF, McCarthy AM, Lanning LD, Delaney C, Porter C. A descriptive study of individuals with membranoproliferative glomerulonephritis. <span><span class="ref-journal">Nephrol Nurs J. </span>2007;<span class="ref-vol">34</span>:295–302.</span> [<a href="/pubmed/17644874" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17644874</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.lu.2012.773">Lu DF, Moon M, Lanning LD, McCarthy AM, Smith RJ. Clinical features and outcomes of 98 children and adults with dense deposit disease. <span><span class="ref-journal">Pediatr Nephrol. </span>2012;<span class="ref-vol">27</span>:773–81.</span> [<a href="/pmc/articles/PMC4423603/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4423603</span></a>] [<a href="/pubmed/22105967" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22105967</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.malik.2012.1155">Malik TH, Lavin PJ, Goicoechea de Jorge E, Vernon KA, Rose KL, Patel MP, de Leeuw M, Neary JJ, Conlon PJ, Winn MP, Pickering MC. A hybrid CFHR3-1 gene causes familial C3 glomerulopathy. <span><span class="ref-journal">J Am Soc Nephrol. </span>2012;<span class="ref-vol">23</span>:1155–60.</span> [<a href="/pmc/articles/PMC3380655/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3380655</span></a>] [<a href="/pubmed/22626820" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22626820</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.marks.2000.322">Marks SD, Rees L. Spontaneous clinical improvement in dense deposit disease. <span><span class="ref-journal">Pediatr Nephrol. </span>2000;<span class="ref-vol">14</span>:322–4.</span> [<a href="/pubmed/10775078" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10775078</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.mart_nezbarricarte.2010.3702">Mart&#x000ed;nez-Barricarte R, Heurich M, Valdes-Ca&#x000f1;edo F, Vazquez-Martul E, Torreira E, Montes T, Tortajada A, Pinto S, Lopez-Trascasa M, Morgan BP, Llorca O, Harris CL, Rodr&#x000ed;guez de C&#x000f3;rdoba S. Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation. <span><span class="ref-journal">J Clin Invest. </span>2010;<span class="ref-vol">120</span>:3702–12.</span> [<a href="/pmc/articles/PMC2947238/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2947238</span></a>] [<a href="/pubmed/20852386" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20852386</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.mathieson.1997.1804">Mathieson PW, Peters DK. Lipodystrophy in MCGN type II: the clue to links between the adipocyte and the complement system. <span><span class="ref-journal">Nephrol Dial Transplant. </span>1997;<span class="ref-vol">12</span>:1804–6.</span> [<a href="/pubmed/9306323" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9306323</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.mccaughan.2012.1046">McCaughan JA, O'Rourke DM, Courtney AE. Recurrent dense deposit disease after renal transplantation: an emerging role for complementary therapies. <span><span class="ref-journal">Am J Transplant. </span>2012;<span class="ref-vol">12</span>:1046–51.</span> [<a href="/pubmed/22233157" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22233157</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.mcrae.2001.6747">McRae JL, Cowan PJ, Power DA, Mitchelhill KI, Kemp BE, Morgan BP, Murphy BF. Human factor H-related protein 5 (FHR-5). A new complement-associated protein. <span><span class="ref-journal">J Biol Chem. </span>2001;<span class="ref-vol">276</span>:6747–54.</span> [<a href="/pubmed/11058592" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11058592</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.mcrae.2005.6250">McRae JL, Duthy TG, Griggs KM, Ormsby RJ, Cowan PJ, Cromer BA, McKinstry WJ, Parker MW, Murphy BF, Gordon DL. Human factor H-related protein 5 has cofactor activity, inhibits C3 convertase activity, binds heparin and C-reactive protein, and associates with lipoprotein. <span><span class="ref-journal">J Immunol. </span>2005;<span class="ref-vol">174</span>:6250–6.</span> [<a href="/pubmed/15879123" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15879123</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.medjeralthomas.2014.933">Medjeral-Thomas N, Malik TH, Patel MP, Toth T, Cook HT, Tomson C, Pickering MC. A novel CFHR5 fusion protein causes C3 glomerulopathy in a family without Cypriot ancestry. <span><span class="ref-journal">Kidney Int. </span>2014;<span class="ref-vol">85</span>:933–7.</span> [<a href="/pmc/articles/PMC3789233/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3789233</span></a>] [<a href="/pubmed/24067434" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24067434</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.merinero.2018.470">Merinero HM, Garc&#x000ed;a SP, Garc&#x000ed;a-Fern&#x000e1;ndez J, Arjona E, Tortajada A, Rodr&#x000ed;guez de C&#x000f3;rdoba S. Complete functional characterization of disease-associated genetic variants in the complement factor H gene. <span><span class="ref-journal">Kidney Int. </span>2018;<span class="ref-vol">93</span>:470–81.</span> [<a href="/pubmed/28941939" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28941939</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.mullins.2001.390">Mullins RF, Aptsiauri N, Hageman GS. Structure and composition of drusen associated with glomerulonephritis: implications for the role of complement activation in drusen biogenesis. <span><span class="ref-journal">Eye (Lond). </span>2001;<span class="ref-vol">15</span>:390–5.</span> [<a href="/pubmed/11450763" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11450763</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.murphy.2002.24">Murphy B, Georgiou T, Machet D, Hill P, McRae J. Factor H-related protein-5: a novel component of human glomerular immune deposits. <span><span class="ref-journal">Am J Kidney Dis. </span>2002;<span class="ref-vol">39</span>:24–7.</span> [<a href="/pubmed/11774097" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11774097</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.nasr.2009.22">Nasr SH, Valeri AM, Appel GB, Sherwinter J, Stokes MB, Said SM, Markowitz GS, D'Agati VD. Dense deposit disease: clinicopathologic study of 32 pediatric and adult patients. <span><span class="ref-journal">Clin J Am Soc Nephrol. </span>2009;<span class="ref-vol">4</span>:22–32.</span> [<a href="/pmc/articles/PMC2615696/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2615696</span></a>] [<a href="/pubmed/18971369" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18971369</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.nava.2017.877">Nava J, Moran S, Figueroa V, Salinas A, Lopez M, Urbina R, Gutierrez A, Lujan JL, Orozco A, Montufar R, Piccoli GB. Successful pregnancy in a CKD patient on a low-protein, supplemented diet: an opportunity to reflect on CKD and pregnancy in Mexico, an emerging country. <span><span class="ref-journal">J Nephrol. </span>2017;<span class="ref-vol">30</span>:877–82.</span> [<a href="/pubmed/28918595" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28918595</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.nester.2016.241">Nester CM, Smith RJ. Complement inhibition in C3 glomerulopathy. <span><span class="ref-journal">Semin Immunol. </span>2016;<span class="ref-vol">28</span>:241–9.</span> [<a href="/pubmed/27402056" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27402056</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.nester.2013a.395">Nester CM, Smith RJ. Diagnosis and treatment of C3 glomerulopathy. <span><span class="ref-journal">Clin Nephrol. </span>2013a;<span class="ref-vol">80</span>:395–403.</span> [<a href="/pubmed/23993166" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23993166</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.nester.2013b.231">Nester CM, Smith RJ. Treatment options for C3 glomerulopathy. <span><span class="ref-journal">Curr Opin Nephrol Hypertens. </span>2013b;<span class="ref-vol">22</span>:231–7.</span> [<a href="/pmc/articles/PMC4437761/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4437761</span></a>] [<a href="/pubmed/23318699" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23318699</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.nicolas.2014.85">Nicolas C, Vuiblet V, Baudouin V, Macher MA, Vrillon I, Biebuyck-Gouge N, Dehennault M, Gi&#x000e9; S, Morin D, Nivet H, Nobili F, Ulinski T, Ranchin B, Marinozzi MC, Ngo S, Fremeaux-Bacchi V, Pietrement C. C3 nephritic factor associated with C3 glomerulopathy in children. <span><span class="ref-journal">Pediatr Nephrol. </span>2014;<span class="ref-vol">29</span>:85–94.</span> [<a href="/pubmed/24068526" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24068526</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.nilsson.2010.172">Nilsson SC, Kalchishkova N, Trouw LA, Fremeaux-Bacchi V, Villoutreix BO, Blom AM. Mutations in complement factor I as found in atypical hemolytic uremic syndrome lead to either altered secretion or altered function of factor I. <span><span class="ref-journal">Eur J Immunol. </span>2010;<span class="ref-vol">40</span>:172–85.</span> [<a href="/pubmed/19877009" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19877009</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.noris.2017.447">Noris M, Remuzzi G. Genetics of immune-mediated glomerular diseases: focus on complement. <span><span class="ref-journal">Semin Nephrol. </span>2017;<span class="ref-vol">37</span>:447–63.</span> [<a href="/pubmed/28863792" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28863792</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.noris.2015.359">Noris M, Remuzzi G. Glomerular diseases dependent on complement activation, including atypical hemolytic uremic syndrome, membranoproliferative glomerulonephritis, and C3 glomerulopathy: core curriculum 2015. <span><span class="ref-journal">Am J Kidney Dis. </span>2015;<span class="ref-vol">66</span>:359–75.</span> [<a href="/pmc/articles/PMC4528072/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4528072</span></a>] [<a href="/pubmed/26032627" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26032627</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.ohi.1992.479">Ohi H, Watanabe S, Fujita T, Yasugi T. Significance of C3 nephritic factor (C3NeF) in non-hypocomplementaemic serum with membranoproliferative glomerulonephritis (MPGN). <span><span class="ref-journal">Clin Exp Immunol. </span>1992;<span class="ref-vol">89</span>:479–84.</span> [<a href="/pmc/articles/PMC1554488/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1554488</span></a>] [<a href="/pubmed/1516262" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1516262</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.osborne.2018.2464">Osborne AJ, Breno M, Borsa NG, Bu F, Fremeaux-Bacchi V, Gale DP, van den Heuvel LP, Kavanagh D, Noris M, Pinto S, Rallapalli PM, Remuzzi G, Rodr&#x000ed;guez de Cordoba S, Ruiz A, Smith RJH, Vieira-Martins P, Volokhina E, Wilson V, Goodship THJ, Perkins SJ. Statistical validation of rare complement variants provides insights into the molecular basis of atypical hemolytic uremic syndrome and C3 glomerulopathy. <span><span class="ref-journal">J Immunol. </span>2018;2018;<span class="ref-vol">200</span>:2464–78.</span> [<a href="/pmc/articles/PMC6324840/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6324840</span></a>] [<a href="/pubmed/29500241" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29500241</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.ossoli.2015.405">Ossoli A, Lucca F, Boscutti G, Remaley AT, Calabresi L. Familial LCAT deficiency: from pathology to enzyme replacement therapy. <span><span class="ref-journal">Clinical Lipidology. </span>2015;<span class="ref-vol">10</span>:405–13.</span></div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.ozaltin.2013.377">Ozaltin F, Li B, Rauhauser A, An SW, Soylemezoglu O, Gonul II, Taskiran EZ, Ibsirlioglu T, Korkmaz E, Bilginer Y, Duzova A, Ozen S, Topaloglu R, Besbas N, Ashraf S, Du Y, Liang C, Chen P, Lu D, Vadnagara K, Arbuckle S, Lewis D, Wakeland B, Quigg RJ, Ransom RF, Wakeland EK, Topham MK, Bazan NG, Mohan C, Hildebrandt F, Bakkaloglu A, Huang CL, Attanasio M. DGKE variants cause a glomerular microangiopathy that mimics membranoproliferative GN. <span><span class="ref-journal">J Am Soc Nephrol. </span>2013;<span class="ref-vol">24</span>:377–84.</span> [<a href="/pmc/articles/PMC3582208/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3582208</span></a>] [<a href="/pubmed/23274426" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23274426</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.paix_ocavalcante.2012.1084">Paix&#x000e3;o-Cavalcante D, L&#x000f3;pez-Trascasa M, Skattum L, Giclas PC, Goodship TH, de C&#x000f3;rdoba SR, Truedsson L, Morgan BP, Harris CL. Sensitive and specific assays for C3 nephritic factors clarify mechanisms underlying complement dysregulation. <span><span class="ref-journal">Kidney Int. </span>2012;<span class="ref-vol">82</span>:1084–92.</span> [<a href="/pmc/articles/PMC3608896/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3608896</span></a>] [<a href="/pubmed/22854646" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22854646</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.piccoli.2018.66">Piccoli GB, Alrukhaimi M, Liu ZH, Zakharova E, Levin A, et al.  What we do and do not know about women and kidney diseases; questions unanswered and answers unquestioned: reflection on World Kidney Day and International Woman's Day. <span><span class="ref-journal">BMC Nephrol. </span>2018;<span class="ref-vol">19</span>:66.</span> [<a href="/pmc/articles/PMC5856379/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5856379</span></a>] [<a href="/pubmed/29544451" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29544451</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.pickering.2013.1079">Pickering MC, D'Agati VD, Nester CM, Smith RJ, Haas M, Appel GB, Alpers CE, Bajema IM, Bedrosian C, Braun M, Doyle M, Fakhouri F, Fervenza FC, Fogo AB, Fremeaux-Bacchi V, Gale DP, Goicoechea de Jorge E, Griffin G, Harris CL, Holers VM, Johnson S, Lavin PJ, Medjeral-Thomas N, Paul Morgan B, Nast CC, Noel LH, Peters DK, Rodr&#x000ed;guez de C&#x000f3;rdoba S, Servais A, Sethi S, Song WC, Tamburini P, Thurman JM, Zavros M, Cook HT. C3 glomerulopathy: consensus report. <span><span class="ref-journal">Kidney Int. </span>2013;<span class="ref-vol">84</span>:1079–89.</span> [<a href="/pmc/articles/PMC3842953/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3842953</span></a>] [<a href="/pubmed/24172683" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24172683</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.rabasco.2015.1153">Rabasco C, Cavero T, Rom&#x000e1;n E, Rojas-Rivera J, Olea T, Espinosa M, Cabello V, Fern&#x000e1;ndez-Juarez G, Gonz&#x000e1;lez F, &#x000c1;vila A, Baltar JM, D&#x000ed;az M, Alegre R, El&#x000ed;as S, Ant&#x000f3;n M, Frutos MA, Pobes A, Blasco M, Mart&#x000ed;n F, Bernis C, Mac&#x000ed;as M, Barroso S, de Lorenzo A, Ariceta G, L&#x000f3;pez-Mendoza M, Rivas B, L&#x000f3;pez-Revuelta K, Campistol JM, Mendiz&#x000e1;bal S, de C&#x000f3;rdoba SR, Praga M, et al.  Effectiveness of mycophenolate mofetil in C3 glomerulonephritis. <span><span class="ref-journal">Kidney Int. </span>2015;<span class="ref-vol">88</span>:1153–60.</span> [<a href="/pubmed/26221755" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26221755</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.recalde.2016.1305">Recalde S, Tortajada A, Subias M, Anter J, Blasco M, Maranta R, Coco R, Pinto S, Noris M, Garc&#x000ed;a-Layana A, Rodr&#x000ed;guez de C&#x000f3;rdoba S. Molecular basis of factor H R1210C association with ocular and renal diseases. <span><span class="ref-journal">J Am Soc Nephrol. </span>2016;<span class="ref-vol">27</span>:1305–11.</span> [<a href="/pmc/articles/PMC4849834/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4849834</span></a>] [<a href="/pubmed/26376859" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26376859</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.riedl.2017.43">Riedl M, Thorner P, Licht C. C3 glomerulopathy. <span><span class="ref-journal">Pediatr Nephrol. </span>2017;<span class="ref-vol">32</span>:43–57.</span> [<a href="/pubmed/27056062" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27056062</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.rodr_guez_de_c_rdoba.2004.355">Rodr&#x000ed;guez de C&#x000f3;rdoba S, Esparza-Gordillo J, Goicoechea de Jorge E, Lopez-Trascasa M, Sanchez-Corral P. The human complement factor H: functional roles, genetic variations and disease associations. <span><span class="ref-journal">Mol Immunol. </span>2004;<span class="ref-vol">41</span>:355–67.</span> [<a href="/pubmed/15163532" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15163532</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.salvadori.2016.632">Salvadori M, Bertoni E. Complement related kidney diseases: recurrence after transplantation. <span><span class="ref-journal">World J Transplant. </span>2016;<span class="ref-vol">6</span>:632–45.</span> [<a href="/pmc/articles/PMC5175220/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5175220</span></a>] [<a href="/pubmed/28058212" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28058212</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.savige.2016.369">Savige J, Amos L, Ierino F, Mack HG, Symons RC, Hughes P, Nicholls K, Colville D. Retinal disease in the C3 glomerulopathies and the risk of impaired vision. <span><span class="ref-journal">Ophthalmic Genet. </span>2016;<span class="ref-vol">37</span>:369–76.</span> [<a href="/pubmed/26915021" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26915021</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.schwertz.2001.166">Schwertz R, Rother U, Anders D, Gretz N, Scharer K, Kirschfink M. Complement analysis in children with idiopathic membranoproliferative glomerulonephritis: a long-term follow-up. <span><span class="ref-journal">Pediatr Allergy Immunol. </span>2001;<span class="ref-vol">12</span>:166–72.</span> [<a href="/pubmed/11473682" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11473682</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.servais.2007.193">Servais A, Fremeaux-Bacchi V, Lequintrec M, Salomon R, Blouin J, Knebelmann B, Gr&#x000fc;nfeld JP, Lesavre P, No&#x000eb;l LH, Fakhouri F. Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome. <span><span class="ref-journal">J Med Genet. </span>2007;<span class="ref-vol">44</span>:193–9.</span> [<a href="/pmc/articles/PMC2598029/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2598029</span></a>] [<a href="/pubmed/17018561" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17018561</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.servais.2013.185">Servais A, No&#x000eb;l LH, Fremeaux-Bacchi V, Lesavre P. C3 glomerulopathy. <span><span class="ref-journal">Contrib Nephrol. </span>2013;<span class="ref-vol">181</span>:185–93.</span> [<a href="/pubmed/23689580" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23689580</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.servais.2012.454">Servais A, Noel LH, Roumenina LT, Le Quintrec M, Ngo S, Dragon-Durey MA, Macher MA, Zuber J, Karras A, Provot F, Moulin B, Gr&#x000fc;nfeld JP, Niaudet P, Lesavre P, Fremeaux-Bacchi V. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. <span><span class="ref-journal">Kidney Int. </span>2012;<span class="ref-vol">82</span>:454–64.</span> [<a href="/pubmed/22456601" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22456601</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.sessa.2001.268">Sessa A, Battini G, Meroni M, Daidone G, Carnera I, Brambilla PL, Vigano G, Giordano F, Pallotti F, Torri Tarelli L, Calabresi L, Rolleri M, Bertolini S. Hypocomplementemic type II membranoproliferative glomerulonephritis in a male patient with familial lecithin-cholesterol acyltransferase deficiency due to two different allelic mutations. <span><span class="ref-journal">Nephron. </span>2001;<span class="ref-vol">88</span>:268–72.</span> [<a href="/pubmed/11423760" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11423760</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.sethi.2011.341">Sethi S, Fervenza FC. Membranoproliferative glomerulonephritis: pathogenetic heterogeneity and proposal for a new classification. <span><span class="ref-journal">Semin Nephrol. </span>2011;<span class="ref-vol">31</span>:341–8.</span> [<a href="/pubmed/21839367" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21839367</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.sethi.2013.293">Sethi S, Fervenza FC, Zhang Y, Zand L, Meyer NC, Borsa N, Nasr SH, Smith RJ. Atypical post-infectious glomerulonephritis is associated with abnormalities in the alternative pathway of complement. <span><span class="ref-journal">Kidney Int. </span>2013;<span class="ref-vol">83</span>:293–9.</span> [<a href="/pmc/articles/PMC3561505/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3561505</span></a>] [<a href="/pubmed/23235567" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23235567</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.sethi.2012a.465">Sethi S, Fervenza FC, Zhang Y, Zand L, Vrana JA, Nasr SH, Theis JD, Dogan A, Smith RJ. C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up. <span><span class="ref-journal">Kidney Int. </span>2012a;<span class="ref-vol">82</span>:465–73.</span> [<a href="/pmc/articles/PMC4438675/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4438675</span></a>] [<a href="/pubmed/22673887" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22673887</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.sethi.2016.1278">Sethi S, Haas M, Markowitz GS, D'Agati VD, Rennke HG, Jennette JC, Bajema IM, Alpers CE, Chang A, Cornell LD, Cosio FG, Fogo AB, Glassock RJ, Hariharan S, Kambham N, Lager DJ, Leung N, Mengel M, Nath KA, Roberts IS, Rovin BH, Seshan SV, Smith RJ, Walker PD, Winearls CG, Appel GB, Alexander MP, Cattran DC, Casado CA, Cook HT, De Vriese AS, Radhakrishnan J, Racusen LC, Ronco P, Fervenza FC. Mayo Clinic/Renal Pathology Society Consensus Report on Pathologic Classification, Diagnosis, and Reporting of GN. <span><span class="ref-journal">J Am Soc Nephrol. </span>2016;<span class="ref-vol">27</span>:1278–87.</span> [<a href="/pmc/articles/PMC4849835/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4849835</span></a>] [<a href="/pubmed/26567243" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26567243</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.sethi.2012b.434">Sethi S, Nester CM, Smith RJ. Membranoproliferative glomerulonephritis and C3 glomerulopathy: resolving the confusion. <span><span class="ref-journal">Kidney Int. </span>2012b;<span class="ref-vol">81</span>:434–41.</span> [<a href="/pmc/articles/PMC4428602/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4428602</span></a>] [<a href="/pubmed/22157657" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22157657</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.smith.2007.2447">Smith RJ, Alexander J, Barlow PN, Botto M, Cassavant TL, Cook HT, de Cordoba SR, Hageman GS, Jokiranta TS, Kimberling WJ, Lambris JD, Lanning LD, Levidiotis V, Licht C, Lutz HU, Meri S, Pickering MC, Quigg RJ, Rops AL, Salant DJ, Sethi S, Thurman JM, Tully HF, Tully SP, van der Vlag J, Walker PD, Wurzner R, Zipfel PF. New approaches to the treatment of dense deposit disease. <span><span class="ref-journal">J Am Soc Nephrol. </span>2007;<span class="ref-vol">18</span>:2447–56.</span> [<a href="/pmc/articles/PMC4853920/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4853920</span></a>] [<a href="/pubmed/17675665" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17675665</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.sohn.2015.48">Sohn EH, Wang K, Thompson S, Riker MJ, Hoffmann JM, Stone EM, Mullins RF. Comparison of drusen and modifying genes in autosomal dominant radial drusen and age-related macular degeneration. <span><span class="ref-journal">Retina. </span>2015;<span class="ref-vol">35</span>:48–57.</span> [<a href="/pmc/articles/PMC5513174/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5513174</span></a>] [<a href="/pubmed/25077532" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25077532</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.sotsiou.2001.68">Sotsiou F. Postinfectious glomerulonephritis. <span><span class="ref-journal">Nephrol Dial Transplant. </span>2001;<span class="ref-vol">16</span> Suppl 6:68–70.</span> [<a href="/pubmed/11568248" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11568248</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.spitzer.1996.211">Spitzer RE, Stitzel AE. Loss of autoantibody activity by alteration in autoantigen. <span><span class="ref-journal">Clin Immunol Immunopathol. </span>1996;<span class="ref-vol">80</span>:211–3.</span> [<a href="/pubmed/8764567" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8764567</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.stone.1999.199">Stone EM, Lotery AJ, Munier FL, Heon E, Piguet B, Guymer RH, Vandenburgh K, Cousin P, Nishimura D, Swiderski RE, Silvestri G, Mackey DA, Hageman GS, Bird AC, Sheffield VC, Schorderet DF. A single EFEMP1 mutation associated with both Malattia Leventinese and Doyne honeycomb retinal dystrophy. <span><span class="ref-journal">Nat Genet. </span>1999;<span class="ref-vol">22</span>:199–202.</span> [<a href="/pubmed/10369267" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10369267</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.strobel.2010.1476">Strobel S, Zimmering M, Papp K, Prechl J, J&#x000f3;zsi M. Anti-factor B autoantibody in dense deposit disease. <span><span class="ref-journal">Mol Immunol. </span>2010;<span class="ref-vol">47</span>:1476–83.</span> [<a href="/pubmed/20193965" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20193965</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.thomas.2014.339">Thomas S, Ranganathan D, Francis L, Madhan K, John GT. Current concepts in C3 glomerulopathy. <span><span class="ref-journal">Indian J Nephrol. </span>2014;<span class="ref-vol">24</span>:339–48.</span> [<a href="/pmc/articles/PMC4244712/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4244712</span></a>] [<a href="/pubmed/25484526" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25484526</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.togarsimalemath.2017.876">Togarsimalemath SK, Sethi SK, Duggal R, Quintrec ML, Jha P, Daniel R, Gonnet F, Bansal S, Roumenina LT, Fremeaux-Bacchi V, Kher V, Dragon-Durey MA. A novel CFHR1-CFHR5 hybrid leads to a familial dominant C3 glomerulopathy. <span><span class="ref-journal">Kidney Int. </span>2017;<span class="ref-vol">92</span>:876–87.</span> [<a href="/pubmed/28729035" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28729035</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.tortajada.2013.2434">Tortajada A, Y&#x000e9;benes H, Abarrategui-Garrido C, Anter J, Garc&#x000ed;a-Fern&#x000e1;ndez JM, Mart&#x000ed;nez-Barricarte R, Alba-Dom&#x000ed;nguez M, Malik TH, Bedoya R, Cabrera P&#x000e9;rez R, L&#x000f3;pez Trascasa M, Pickering MC, Harris CL, S&#x000e1;nchez-Corral P, Llorca O, Rodr&#x000ed;guez de C&#x000f3;rdoba S. C3 glomerulopathy-associated CFHR1 mutation alters FHR oligomerization and complement regulation. <span><span class="ref-journal">J Clin Invest. </span>2013;<span class="ref-vol">123</span>:2434–46.</span> [<a href="/pmc/articles/PMC3668852/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3668852</span></a>] [<a href="/pubmed/23728178" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23728178</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.vaclavik.2016">Vaclavik V, Munier FL. Malattia Leventinese (autosomal dominant drusen). In: Querques G, Souied E, eds. <em>Macular Dystrophies</em>. Cham, Switzerland: Springer; 2016: 39-51.</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.vernon.2012.121">Vernon KA, Goicoechea de Jorge E, Hall AE, Fremeaux-Bacchi V, Aitman TJ, Cook HT, Hangartner R, Koziell A, Pickering MC. Acute presentation and persistent glomerulonephritis following streptococcal infection in a patient with heterozygous complement factor H-related protein 5 deficiency. <span><span class="ref-journal">Am J Kidney Dis. </span>2012;<span class="ref-vol">60</span>:121–5.</span> [<a href="/pmc/articles/PMC3382710/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3382710</span></a>] [<a href="/pubmed/22503529" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22503529</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.vivarelli.2014.472">Vivarelli M, Emma F. Treatment of C3 glomerulopathy with complement blockers. <span><span class="ref-journal">Semin Thromb Hemost. </span>2014;<span class="ref-vol">40</span>:472–7.</span> [<a href="/pubmed/24799307" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24799307</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.walker.2007.605">Walker PD, Ferrario F, Joh K, Bonsib SM. Dense deposit disease is not a membranoproliferative glomerulonephritis. <span><span class="ref-journal">Mod Pathol. </span>2007;<span class="ref-vol">20</span>:605–16.</span> [<a href="/pubmed/17396142" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17396142</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.west.2000.786">West CD, McAdams AJ, Witte DP. Acute non-proliferative glomerulitis: a cause of renal failure unique to children. <span><span class="ref-journal">Pediatr Nephrol. </span>2000;<span class="ref-vol">14</span>:786–93.</span> [<a href="/pubmed/10955928" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10955928</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.westland.2014.1408">Westland R, Bodria M, Carrea A, Lata S, Scolari F, Fremeaux-Bacchi V, D'Agati VD, Lifton RP, Gharavi AG, Ghiggeri GM, Sanna-Cherchi S. Phenotypic expansion of DGKE-associated diseases. <span><span class="ref-journal">J Am Soc Nephrol. </span>2014;<span class="ref-vol">25</span>:1408–14.</span> [<a href="/pmc/articles/PMC4073436/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4073436</span></a>] [<a href="/pubmed/24511134" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24511134</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.xiao.2016.89">Xiao X, Ghossein C, Tortajada A, Zhang Y, Meyer N, Jones M, Borsa NG, Nester CM, Thomas CP, de C&#x000f3;rdoba SR, Smith RJ. Familial C3 glomerulonephritis caused by a novel CFHR5-CFHR2 fusion gene. <span><span class="ref-journal">Mol Immunol. </span>2016;<span class="ref-vol">77</span>:89–96.</span> [<a href="/pubmed/27490940" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27490940</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.xiao.2014.465">Xiao X, Pickering MC, Smith RJH. C3 glomerulopathy: the genetic and clinical findings in dense deposit disease and C3 glomerulonephritis. <span><span class="ref-journal">Semin Thromb Hemost. </span>2014;<span class="ref-vol">40</span>:465–71.</span> [<a href="/pubmed/24799308" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24799308</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.zand.2014.1110">Zand L, Lorenz EC, Cosio FG, Fervenza FC, Nasr SH, Gandhi MJ, Smith RJ, Sethi S. Clinical findings, pathology, and outcomes of C3GN after kidney transplantation. <span><span class="ref-journal">J Am Soc Nephrol. </span>2014;<span class="ref-vol">25</span>:1110–7.</span> [<a href="/pmc/articles/PMC4005307/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4005307</span></a>] [<a href="/pubmed/24357668" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24357668</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.zhang.2017.834">Zhang Y, Meyer NC, Fervenza FC, Lau W, Keenan A, Cara-Fuentes G, Shao D, Akber A, Fremeaux-Bacchi V, Sethi S, Nester CM, Smith RJ. C4 nephritic factors in C3 glomerulopathy: a case series. <span><span class="ref-journal">Am J Kidney Dis. </span>2017;<span class="ref-vol">70</span>:834–43.</span> [<a href="/pmc/articles/PMC5701858/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5701858</span></a>] [<a href="/pubmed/28838767" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28838767</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.zhang.2012.265">Zhang Y, Meyer NC, Wang K, Nishimura C, Frees K, Jones M, Katz LM, Sethi S, Smith RJ. Causes of alternative pathway dysregulation in dense deposit disease. <span><span class="ref-journal">Clin J Am Soc Nephrol. </span>2012;<span class="ref-vol">7</span>:265–74.</span> [<a href="/pmc/articles/PMC3280037/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3280037</span></a>] [<a href="/pubmed/22223606" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22223606</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.zhang.2013.1820">Zhang Y, Nester CM, Holanda DG, Marsh HC, Hammond RA, Thomas LJ, Meyer NC, Hunsicker LG, Sethi S, Smith RJ. Soluble CR1 therapy improves complement regulation in C3 glomerulopathy. <span><span class="ref-journal">J Am Soc Nephrol. </span>2013;<span class="ref-vol">24</span>:1820–9.</span> [<a href="/pmc/articles/PMC3810083/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3810083</span></a>] [<a href="/pubmed/23907509" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23907509</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.zhu.2016.f895">Zhu J, Chaki M, Lu D, Ren C, Wang SS, Rauhauser A, Li B, Zimmerman S, Jun B, Du Y, Vadnagara K, Wang H, Elhadi S, Quigg RJ, Topham MK, Mohan C, Ozaltin F, Zhou XJ, Marciano DK, Bazan NG, Attanasio M. Loss of diacylglycerol kinase epsilon in mice causes endothelial distress and impairs glomerular Cox-2 and PGE2 production. <span><span class="ref-journal">Am J Physiol Renal Physiol. </span>2016;<span class="ref-vol">310</span>:F895–908.</span> [<a href="/pmc/articles/PMC4867310/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4867310</span></a>] [<a href="/pubmed/26887830" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26887830</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.zipfel.2015.21">Zipfel PF, Skerka C, Chen Q, Wiech T, Goodship T, Johnson S, Fremeaux-Bacchi V, Nester C, de C&#x000f3;rdoba SR, Noris M, Pickering M, Smith R. The role of complement in C3 glomerulopathy. <span><span class="ref-journal">Mol Immunol. </span>2015;<span class="ref-vol">67</span>:21–30.</span> [<a href="/pubmed/25929733" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25929733</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mpgn.REF.zipfel.2006">Zipfel PF, Smith RJH, Heinen ST. The role of complement in membranoproliferative glomerulonephritis. In: Zipfel PF, ed. <em>Complement and Kidney Disease</em>. Berlin, Germany: Springer; 2006:199-221.</div></li></ul></div></div><div id="mpgn.Chapter_Notes"><h2 id="_mpgn_Chapter_Notes_">Chapter Notes</h2><div id="mpgn.Author_Notes"><h3>Author Notes</h3><p><b>Contact Information</b></p><p>Richard JH Smith <br />Division of Nephrology <br />University of Iowa <br />200 Hawkins Drive <br />Iowa City, IA 52242 <br />Telephone: 319-356-3612 <br />Fax: 319-356-4108 <br />Email: richard-smith@uiowa.edu</p></div><div id="mpgn.Acknowledgments"><h3>Acknowledgments</h3><p>Supported in part by grant RO1-DK110023 from the NIDDK (RJHS)</p></div><div id="mpgn.Author_History"><h3>Author History</h3><p>Johnny Cruz Corchado; University of Iowa (2011-2018)<br />Bertha Mart&#x000ed;n (2018-present)<br />Sanjeev Sethi, MD, PhD; Mayo Clinic (2007-2011)<br />Richard JH Smith, MD (2007-present)<br />Peter F Zipfel, PhD habil Prof; Hans Kn&#x000f6;ll Institute (2007-2011)</p></div><div id="mpgn.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>5 April 2018 (ha) Comprehensive update posted live</div></li><li class="half_rhythm"><div>19 May 2011 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>2 January 2008 (rjhs/cd) Revision: clinical testing (<a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>) for <i>CFHR5</i> mutations</div></li><li class="half_rhythm"><div>20 July 2007 (me) Review posted live</div></li><li class="half_rhythm"><div>17 August 2005 (rjhs) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1425</span><span class="label">PMID: <a href="/pubmed/20301598" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301598</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/burn-mckeown/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/als-ftd/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1425&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1425/?report=reader">PubReader</a></li><li><a href="/books/NBK1425/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1425" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1425" style="display:none" title="Cite this Page"><div class="bk_tt">Martín B, Smith RJH. C3 Glomerulopathy. 2007 Jul 20 [Updated 2018 Apr 5]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1425/pdf/Bookshelf_NBK1425.pdf">PDF version of this page</a> (1.1M)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#mpgn.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#mpgn.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#mpgn.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#mpgn.Genetically_Related_Allelic_Disorde" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#mpgn.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#mpgn.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#mpgn.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#mpgn.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#mpgn.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#mpgn.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#mpgn.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=81494[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">CFHR5</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=718[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">C3</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=3075[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">CFH</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=8526[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">DGKE</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=3426[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">CFI</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1468218" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1468218" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1468218" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1468218" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301541" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Genetic Atypical Hemolytic-Uremic Syndrome</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Genetic Atypical Hemolytic-Uremic Syndrome<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Noris M, Bresin E, Mele C, Remuzzi G. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/31820418" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Outcome of C3 glomerulopathy patients: largest single-centre experience from South Asia.</a><span class="source">[J Nephrol. 2019]</span><div class="brieflinkpop offscreen_noflow">Outcome of C3 glomerulopathy patients: largest single-centre experience from South Asia.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Kumar A, Nada R, Ramachandran R, Rawat A, Tiewsoh K, Das R, Rayat CS, Gupta KL, Vasishta RK. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">J Nephrol. 2019 Dec 9; . Epub 2019 Dec 9.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/25341722" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Defining the complement biomarker profile of C3 glomerulopathy.</a><span class="source">[Clin J Am Soc Nephrol. 2014]</span><div class="brieflinkpop offscreen_noflow">Defining the complement biomarker profile of C3 glomerulopathy.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Zhang Y, Nester CM, Martin B, Skjoedt MO, Meyer NC, Shao D, Borsa N, Palarasah Y, Smith RJ. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Clin J Am Soc Nephrol. 2014 Nov 7; 9(11):1876-82. Epub 2014 Oct 23.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/26895476" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome.</a><span class="source">[Mol Immunol. 2016]</span><div class="brieflinkpop offscreen_noflow">Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Iatropoulos P, Noris M, Mele C, Piras R, Valoti E, Bresin E, Curreri M, Mondo E, Zito A, Gamba S, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Mol Immunol. 2016 Mar; 71:131-142. Epub 2016 Feb 16.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/23689580" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> C3 glomerulopathy.</a><span class="source">[Contrib Nephrol. 2013]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> C3 glomerulopathy.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Servais A, Noël LH, Frémeaux-Bacchi V, Lesavre P. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Contrib Nephrol. 2013; 181:185-93. Epub 2013 May 8.</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301598" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301598" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e040e77dde0891169658de9">C3 Glomerulopathy - GeneReviews®</a><div class="ralinkpop offscreen_noflow">C3 Glomerulopathy - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T20:35:51-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal106&amp;ncbi_phid=CE8D1A2BE03FC6010000000006EE026D&amp;ncbi_session=CE8D1A2BE040E761_1774SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1425%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1425&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1425/&amp;ncbi_pagename=C3 Glomerulopathy - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8D1A2BE040E761_1774SID /projects/books/PBooks@5.22 portal106 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>